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Abstract
Selective Endothelin Receptor Involvement in the Development of 
Colorectal Cancer and Liver Metastases
Endothelin-1 (ET-1), a vasoactive peptide with mitogenic qualities, is over­
expressed in the plasma of patients with colorectal cancer (CRC) and liver 
metastases. Its actions are mediated via two G-protein linked receptors, ETA 
and ETb. This study (i) examined the effect of ET-1 and its receptor 
antagonists as well as a G-protein blocker on CRC cell line growth; (ii) 
investigated tET receptor distribution in human CRC and liver metastases by 
autoradiography; (iii) recorded the effect on tumour growth of an oral ETA 
receptor antagonist to an in vivo model of colorectal cancer liver metastases. 
ET-1 stimulated significant growth in the cancer cells. This effect was 
reversed by the ETA, but not the ETB, receptor antagonist. Apoptosis was 
similar in controls and ET-1± antagonist treated cells. BrDU staining 
demonstrated an ET-1 dependent increase in mitosis, reversed by the ETA 
receptor antagonist. Blocking the G-protein subunits also reversed growth. In 
human cancer tissues ETA was over-expressed while ETB was under­
expressed compared to controls. There was no significant difference in weight 
or number of liver metastases between control and experimental rats in vivo.
In summary, ET-1 stimulates human CRC growth in vitro via ETA receptors by 
mechanisms that include stimulation of mitosis but not alteration of apoptosis. 
Thi signal is transduced via the G-protein subunits Go or Gi. Human CRC 
liver metastases tissue over-express ETA receptors compared to normal 
tissue. ET receptor antagonists may have a therapeutic role in primary and 
metastatic CRC.
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CHAPTER I 
Review of Literature
12
Colorectal cancer is one of the commonest cancers in the West. Despite 
improvements in surgical and oncological treatment, survival at 5 years 
remains at 50% and one of the main factors for this poor outcome is the high 
rate of liver metastases. There is an increasing understanding of the 
underlying genetic and cellular biology of this disease. Endothelin-1 (ET-1) 
has a role to play in the development of colorectal cancer and its metastases.
It may therefore be possible to use ET receptor antagonists in the treatment 
of colorectal cancer metastases. The introduction reviews current knowledge 
of ET-1 with special emphasis on its role in cancer generally and colorectal 
cancer specifically.
1.1 Endothelins
1.1.1 Introduction
A family of peptides found to cause coronary vasoconstriction in 1985 (Hickey et al, 
1985) was subsequently isolated and identified in 1988 (Yanagisawa et al, 1988), 
and named endothelins (ET). There are three recognised members of this family - 
endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3) - which are 21 
amino acid peptides and act as modulators of vasomotor tone, cell proliferation and 
hormone production in a variety of tissues. However, more recently Kishi (1998) 
described a 31 amino acid peptide with potent vasocontractile activity which was 
inhibited by both endothelin receptors A and B (ETA and ETB) specific antagonists. 
Collectively, the ET family ligands, precursors and associated enzymes and the ET 
receptors are called the “ET axis” (Nelson JB et al, 1999).
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1.1.2 Structure
Preproendothelin-1 is 212 amino acids long and is processed to the 38 amino acid 
prohormone big endothelin-1, which is secreted and circulates in the plasma. The 
glycoprotein enzyme endothelin-converting enzyme (ECE)(Yanagisawa et al, 1988) 
cleaves big endothelin-1 between positions 21 (tryptophan) and 22 (valine) to 
generate ET-1.
1.1.3 Gene Regulation
The genes for ET-1, ET-2 and ET-3 have been localised to human chromosomes 6,
1 and 20 respectively (Bloch et al, 1989; 1991; Arinami et al, 1991). In general, the 
expression pattern of the ET genes is analogous to the tissue localisation pattern of 
ET receptors (Haynes et al, 1993) and suggests that ET is most likely a local 
mediator, acting as an autocrine or paracrine factor.
It is generally known that little, if any, ET-1 is stored in endothelial cells under 
physiological conditions and therefore must be made constitutively and then 
released from the cells. Endothelial cell expression of preproET-1 mRNA is known to 
be altered by a number of factors, including haemodynamic shear stress (Morita et 
al, 1993), hypoxia (Kourembanas et al, 1991), transforming growth factor-p (TGF- 
p)(Kurihara et al, 1989), tumour necrosis factor-a (TNF-a)(Marsden PA et al, 1992) 
and thrombin (Yanagisawa et al, 1988). Endothelin production is inhibited by agents 
that stimulate intracellular cGMP levels, including endothelium derived relaxing 
factor (EDRF), nitrovasodilators, prostaglandins and heparin (Saijonmaa et al, 1990; 
Boulanger et al, 1991; Kohno et al, 1992; 1993; Imai et al, 1993; Yokokawa et al, 
1993)
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1.1.4 Local Production
Endothelial cells appear to be the primary source of ET circulating in plasma. It is, 
however, possible that a variety of other cell types may release ET as happens in a 
wide range of cultured cells. The isoform of ET most prevalent in culture media and 
in body fluids or tissue is ET-1. ET-3 may be predominant in some tissues, 
particularly gut and brain. ET-2 has been difficult to detect by readily available 
methods due to cross-reactivity of most antibodies with ET-1 and therefore, little is 
known about it.
Localisation studies using molecular probes have shown that ET-1 is made where it 
is likely to have an effect, supporting the hypothesis that ET-1 is a paracrine factor. 
ET-1 produced by human umbilical vein endothelial cells and grown to confluent 
monolayers on acellular amniotic membranes has been shown to release 
predominantly into the basolateral compartment. ET-1 is thus released toward what 
would be the underlying vascular smooth muscle cells of the vessel intima (Wagner 
OF et al, 1992).
1.1.5 Clearance from Plasma
ET is thought to be removed from the circulation and extra-circulatory spaces by 
binding to its receptors (ETB) followed by internalisation, uncoupling and enzymatic 
degradation. Because of this high capacity clearance mechanism, free and intact ET 
would be expected to be scarce in biological tissue or fluid, as measurements of ET 
levels by immunoassay have demonstrated.
1.1.6 Endothelin-1
Endothelin-1 (ET-1) is produced in both endothelial and vascular smooth muscle
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cells. As much as 75% of ET-1 secretion from cultured endothelial cells is towards 
the vascular smooth muscle side of the cells, where it can bind to specific receptors 
to cause vasoconstriction. While it is unlikely that this pool of ET-1 contributes to the 
plasma concentration it remains, nevertheless, useful to measure plasma 
endothelin-1 levels as they have been found to correlate well with severity of 
disease, such as in congestive cardiac failure (Wei C-M et al, 1994). ET-1 probably 
has a role in the maintenance of basal vasomotor tone. The infusion of BQ-123, a 
selective antagonist of ETA receptors, into the brachial artery of normal subjects 
caused progressive vasodilation and a 64% increase in forearm blood flow after one 
hour (Haynes WG et al, 1994). Although each of the endothelins is capable of 
producing vasoconstriction, ET-1 is the most potent vasoconstrictor known to man 
for it is 100 times more potent than noradrenaline on a molar basis. ET-1 also 
potentiates the vasoconstriction caused by noradrenaline (Tabuchi et al, 1989) and 
vice versa.
1.1.7 Endothelin-2 and Endothelin-3
Endothelin-2 (ET-2) is produced predominantly within the kidney and intestine but 
the cells of origin are unclear. It has no unique physiological functions as compared 
to ET-1.
Endothelin-3 (ET-3), like ET-1, circulates in the plasma. It has been found 
ubiquitously in the brain, the gastrointestinal tract, the kidneys and lungs.
1.2 Endothelin Receptors
The endothelins bind to two types of receptors (A & B) in mammalian tissue. The
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receptors are members of the super family of receptors linked with guanine- 
nucleotide-binding (G) proteins and range from 45,000 to 50,000 daltons in size in 
various tissues. The amino acid structure of the two types of receptor is 
approximately 50% identical.
The human ETA and ETB receptor genes have been assigned to chromosome 4 
(Hosoda et al, 1992) and chromosome 13 (Arai et al, 1993) respectively. A third 
receptor type, ETC, which selectively responds to ET-3 has been identified and 
cloned in Xenopus laevis dermal melanophore (Karne et al, 1993). A mammalian 
equivalent has not been identified.
The greatest similarity between ETA and ETB receptors is in the trans-membrane 
regions and the intracellular loops. The greatest dissimilarities are found in the N- 
termini and extracellular loops 1 and 3. Alteration of the N-terminal extracellular 
region alters ET-1 binding to the human ETA receptor (Hashido et al, 1992) and 
results in differential binding affinity for the latter (ET-1>ET-2>ET-3).
1.2.1 Localisation and Function
ETa is relatively abundant in human lung, aorta and heart and much less abundant 
in liver, pancreas, kidney, brain, adrenal, gut and skeletal muscle (Hosoda et al, 
1992; Hori et al, 1992; Elshourbagy et al, 1993). ETB is relatively abundant in 
cerebral cortex, cerebellum, liver, kidney, lung and placenta and much less 
abundant in pancreas, gut, heart and skeletal muscle (Elshourbagy et al, 1993). In 
general, within the vascular wall, smooth muscle cells mainly express ETA and 
endothelial cells mainly express ETB receptors (Hosoda et al, 1991). However, this 
generalisation is somewhat controversial in the light of results from functional 
studies. Moreland (1994) concluded from their functional studies, using BQ-123 and
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sarafotoxin S6c ( a selective ETB receptor agonist), that ETA receptors predominate 
on the high pressure (arterial) side of the circulation and ETB receptors predominate 
on the low pressure (venous) side of the circulation. Thus it seems clear that ET-1 
can produce contraction in arteries (i.e., vascular smooth muscle cells) via either an 
ETa or ETB-mediated pathway.
1.2.2 Endothelin Receptor Nomenclature and Subclassification
Though only two mammalian endothelin receptors have been isolated, cloned and 
expressed to date, the existence of additional endothelin receptors and/or endothelin 
receptor subtypes have been postulated based on pharmacological studies that 
cannot be explained on the basis of only the ETA and ETB receptor.
ETa receptor subtypes: Initial work relating to the classification of endothelin 
responses suggested that endothelin-induced vasoconstriction was mediated by the 
ETa receptor situated on vascular smooth muscle cells. There are numerous 
examples demonstrating inhibition of ET-1 induced vasoconstriction and mitogenesis 
by the ETA receptor antagonist BQ-123 (lhara M et al, 1992a). Karaki and 
colleagues (1993) observed that some ETA receptor mediated responses were 
insensitive to inhibition by BQ-123, and they therefore proposed the existence of ETA 
subtypes. It was postulated that the ETAi receptor represented a subtype which is 
sensitive to inhibition by BQ-123 while ETA2 is insensitive to this type of inhibition. 
ETb receptor subtypes: There are numerous examples of pharmacological data 
indicating the existence of anatomically separate and distinct ETB receptor subtypes; 
an ETb receptor on the endothelium that produces the release of nitric oxide to 
mediate vasodilation, and a subtype on vascular smooth muscle that directly 
mediates vasoconstriction (Warner TD et al, 1993a; b; Douglas SA et al, 1995). ETBi
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was the name given to those ETB receptors upon which the compound IRL1038 
acted as selective antagonist and the compound PD142893 acted as a non-selective 
antagonist (Warner TD et al, 1993a). The ETB2 agonists were not affected by either 
of those compounds (Sudjarwo et al, 1993). The ETB1 receptors are in the 
endothelium and bring about the release of relaxing factors, while the ETB2 receptors 
are found in vascular smooth muscle and when activated cause vasoconstriction. 
Other endothelin receptors: The ETC receptor displays more affinity with ET-3 
than with ET-1. It appears to trigger nitrous oxide (NO) release (Karne et al, 1993). 
Until now no homologous receptor has been discovered for it in mammal cells.
1.2.3 Cellular Mechanisms
Attempts have been made to explain the mechanism of action of ET on vascular 
smooth muscle. The vasoconstrictor response is affected by two types of receptor, 
ETa and ETB2. This vasoconstriction is correlated with a maintained heightening of 
intracellular calcium (Ca2+) produced via a two-phase mechanism. The binding of 
ET-1 to the receptor activates phospholipase C which hydrolyses 
phosphotidilinositol-4,5-biphosphate (PIP2) into two products, inositol triphosphate 
(IP3) and diacilglycerol (DAG). The initial increase in Ca2+ concentration is caused 
by rapid mobilisation of intracellular Ca2+ stores by IP3. This initial amount of Ca2+ 
entering would be able to depolarise the vascular smooth muscle sufficiently for this 
in turn to activate the L-type voltage-dependent Ca2+ channels. Contraction could 
also be partially affected by the action of another product of PIP2 hydrolysis, namely 
DAG.
In addition to the vasoactive effects, ET-1 promotes proliferation of vascular 
endothelial cells (via ETB) and of vascular smooth muscle (via ETA) and fibroblasts
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(via both receptors) resulting in structural changes to the vessel wall. The mitogenic 
effect of ET-1 is attributed to stimulation of tyrosine residues as well as 
phosphorylation and activation of two other mitogen-activated protein kinases in the 
vascular smooth muscle (Golfman et al, 1993; Hirata et al, 1989; Bobik et al, 1990).
1.3 Endothelin Antagonists
Experimental and clinical evidence exists to support the importance of the 
development of drugs that block the production or actions of ET for use in 
cardiovascular medicine and oncology, particularly in conditions in which these 
peptides are clearly implicated.
The first ET receptor antagonists were of a peptide nature. In the development of 
these compounds, it was discovered that ETA receptors recognise the tertiary 
structure of the N-terminal and C-terminal portion of the ET molecules. However,
ETb receptors only recognise the structure of the C-terminal portion. In 1991 based 
on these conclusions the first described ET antagonist, IRL1038, was developed; 
this was a selective in vivo inhibitor of ETB receptors capable of antagonising ET-1 
and ET-3-induced contractions in guinea pig ileum (Sakurai et al, 1993). The first 
attempt at obtaining a selective ETA receptor antagonist was made by taking a 
fragment of ET peptide with a modification of the disulphide bridges and with the 
introduction of a diaminopropionic acid in the structure. The compound thereby 
obtained inhibited the ET-1-induced contraction, but not that induced by ET-3 in the 
pulmonary arteries (Spinella et al, 1991). Based on these studies the compound BQ- 
123 was introduced. The latter is now accepted to be the gold standard compound 
for ET receptor identification (lhara et al, 1992). The potency of ET antagonists
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varies according to what we consider to be their short or long term action. In this way 
it was discovered that BQ-123 totally blocks the production of IP3 provoked by ET-1 
in vascular smooth muscle cells, but not the mitogenic effect on them. 
Competitiveness studies show that this loss of long term activity is not related to the 
degradation of the compound, but rather with dissociation processes. Another ETA 
receptor antagonist of a peptide nature which has been developed is the compound 
BQ-610. This compound antagonises cerebral vasoconstriction produced by 
subarachnoid haemorrhage, which is thought to be mediated by endogenous ET-1 
acting through ETA receptors (Zuccarello et al, 1994).
Non-peptide ET antagonists have also been developed. The first was the compound 
50-235 that was a selective ETA receptor agonist with no effect on ETB (Mihara et al, 
1993). Some of the later compounds developed did not have heightened selectivity 
for one receptor or the other and were therefore considered to be ETA/ETB receptor 
antagonists. The best known non-peptide antagonist is the compound Ro-47-0203, 
also known as Bosentan. Bosentan shows 20 to 50-fold selectivity for the ETA 
receptor in studies of the inhibition of [125I]ET-1 binding to recombinant human 
receptors. In functional studies, however, it was somewhat less selective (Clozel et 
al, 1994). Other studies have shown that the systemic administration of Bosentan to 
patients with severe chronic heart failure produces systemic, pulmonary and 
peripheral venous vasodilation and improved cardiac performance, without causing 
reflex tachycardia (Kiowski et al, 1995). On the other hand it should be pointed out 
that the compound BQ-788 is a non-peptide antagonist selective for ETB receptors. 
This compound has been widely used in animal experiments for the characterisation 
of receptors which mediate the effects of ET. It can potentiate the arterial blood 
pressure increases induced by ET-1 and this is because it blocks the ETB receptors
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in the endothelium and vascular smooth muscle; as a result, their initial vasodilator 
effect is sometimes lost (Ishikawa et al, 1994).
A novel class of orally active non-peptide ETA antagonists has been discovered by 
high throughput screening. The compounds are ETA selective, are orally available 
and show a long duration of action (Riechers et al, 1996). One of these is the 
compound A-127722, the most potent ET receptor antagonist disclosed to date, 
which has a more than 1000-fold greater affinity for binding to human ETA receptors 
than to human ETB receptors. It has been shown to be orally bio-available in the rat, 
dog and monkey. In the conscious rat, A-127722 exhibits a dose-related inhibition of 
the blood pressure response to exogenous ET-1 (Opgenorth et al, 1996).
The use of ET antagonists in cancer has demonstrated some benefit and further 
potential. Ali (2000b) demonstrated the mitogenic effect of ET-1 on human colorectal 
cancer cell lines in vitro. This action was inhibited by the application of the ETA 
antagonist BQ-123. Moraitis (1997) and a group led by Bagnato (1997) also 
demonstrated similar results whilst working on ovarian cancer cell lines in vitro. 
Similar results in prostate cancer cell lines underpin ongoing clinical trials using ETA 
antagonists in prostate cancer (Zonnenberg et al, 2003; Carducci et al, 2003). The 
proliferation of three human pancreatic carcinoma cell lines expressing ETA 
receptors was significantly reduced using a selective ETA antagonist (Bhargava S et 
al, 2005). In vivo, the selective ETA inhibition resulted in reduced angiogenesis as 
measured by lower microvessel densities (Bhargava et al, 2005). The biological 
mechanisms of ET-1 action in cancer are described further on in this thesis.
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1.4 Endothelin-1 and Cardiovascular Disease
The endothelins are involved in the patho-physiological mechanism of a number of 
vascular conditions. Evidence now suggests a role for ET in sustained 
vasoconstriction as seen in hypertension and heart failure, local ischaemia as in 
myocardial infarction and acute renal failure and vasospasm as in Raynaud’s 
disease and subarachnoid haemorrhage.
Possibly all isoforms of ET may be involved in the pathogenesis of hypertension 
through several effects. In addition to increasing central (Nishimura et al, 1991) and 
peripheral (Wong-Dusting et al, 1990) sympathetic activity, it stimulates the 
generation of renin, angiotensin II, aldosterone (Rakugi et al, 1990), as well as the 
generation of adrenaline (Boarder et al, 1989). Besides its vasoconstrictor and 
pressor effect, ET-1 has positive inotropic properties (Ishikawa et al, 1988; 
McClellan G et al, 1996) and an antinatriuretic action (Rabelink et al, 1994). In 
moderate to severe human essential hypertension the expression of ET-1 gene is 
increased though plasma levels of ET-1 are only slightly elevated in experimental 
and human hypertension. This may be due to the fact that ET synthesised in the 
endothelium is mostly released towards the underlying smooth muscle cells.
The plasma concentration of Big ET-1 correlates well with the severity of heart 
failure and is the most powerful predictor of outcome (Masson S et al, 2006). 
Ischaemia can induce synthesis of endothelins. In humans, plasma endothelial 
levels are increased in acute myocardial infarction and unstable angina and the 
higher the plasma endothelin level in myocardial infarction and unstable angina the 
worse the prognosis (Miyauchi et al, 1989). Plasma ET levels on the third day after 
myocardial infarction are significantly related to mortality and plasma ET levels at 9
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weeks after hospitalisation with unstable angina are significantly related to the 
incidence of further cardiovascular events (Omland T et al, 1994).
ET has been implicated in the acute renal failure and hypertension associated with 
nephrotoxic agents such as cyclosporin (Kon et al, 1990). The renal vasculature is 
very sensitive to ET and administration of ET antagonists 24 hrs after the ischaemic 
event still provided marked protection against severe acute renal failure (Gellai et al, 
1995). ET-1 anatgonists also play a role in the treatment of patiernts with pulmonary 
hypertension (Barst RJ et al, 2006).
ET is a potent vasoconstrictor of isolated cerebral arteries and its effects are 
potentiated after subarachnoid haemorrhage (Alafaci et al, 1990).
1.5 Endothelin-1 and Cancer
ET-1 has been found to act as a mitogen for human epithelial carcinoma cell lines in 
vitro (Shichiri et al, 1991). The known ET-1 positive mitogenic effects affect 
fibroblasts and cancer cells (Kusuhara et al, 1989; 1990). Elevated levels of ET-1 
have been found in specimens of cancer tissue including prostate (Nelson J et al, 
1995), colon (Asham et al, 1997), breast (Patel et al, 1995) and thyroid (Donckier J 
et al, 2004). Patients with primary or metastatic colorectal and primary liver cancers 
are also known to have elevated plasma ET-1 levels (Shankar et al, 1996;
Nakamuta et al, 1993). ET receptors are upregulated in specimens of prostate 
(Nelson J et al, 1995), lung (Zhao et al, 1995), breast (Wulfing P et al, 2004) and 
thyroid papillary (Donckier J et al, 2004) cancers. In in vitro systems, ovarian cancer 
cell lines produce ET-1 and possess ETA receptors (Bagnato et al, 1997). Bagnato, 
Moraitis and others, working on ovarian cancer cell lines, also found that addition of
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exogenous ET resulted in specific dose-dependent increases in cell number for ET-1 
and ET-2 but not for ET-3. In the presence and absence of the exogenous peptides, 
the addition of BQ-123 reduced the cell number. This result is consistent with ET-1 
acting via ETA receptors as a positive mitogen (Moraitis et al, 1997; Bagnato et al, 
1997) and is discussed further in section 1.5.2.
Tumourigenesis is dependent on the parallel development of a vascular 
supply (Folkman J, 1972). The vessels originate from the host circulation and 
their development correlates positively with the metastatic potential of the 
tumour (Folkman J, 1971; 1972). Recent studies have attempted to 
manipulate the vessel growth in several cancers with a view to inhibiting 
growth of the primary and subsequent metastases. ET-1, a recognised 
vasoconstrictor peptide, has been implicated as an angiogenic agent (Dawas 
et al, 1999, Knowles et al, 2005). With the recent development of ET-1 
antagonists, the manipulation of angiogenesis within tumours may be 
possible.
1.5.1 The Role of Angiogenesis in Cancer Development
Most solid human tumours will exist in situ for a substantial length of time without the 
need for vascularisation (Folkman J in The Molecular Basis of Cancer, 1995). 
Vascularisation is necessary for progression of the neoplasm beyond 2-3mm3 and 
its ability to metastasise (Folkman J, 1971; Weidner N, 1995). A “switch”, occurring 
in some of the tumour cells, to an angiogenic phenotype initiates vascularisation 
(Folkman J in The Molecular Basis of Cancer, 1995). This “switch” involves a 
change in the steady state equilibrium between positive and negative regulators of 
microvessel growth (Dameron et al, 1994).
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The process of tumour angiogenesis starts with vessels and tumour growing towards 
each other (Harris A, 1997). Driven by angiogenic factors (bFGF, VEGF, tumour 
necrosis factor-p and PDGF) and dampened by the down-regulation of certain 
angiogenic inhibitors (angiostatin, endostatin, platelet factor 4 and interleukin 1), 
these “driven” endothelial cells divide much more rapidly than normal endothelial 
cells. The endothelial basement membrane is degraded initiating new vessel 
sprouting. The new tumour vasculature is abnormal in that it is leaky, thus allowing 
passage of fibrinogen and plasminogen. Effectively, the normal process of 
angiogenesis is incomplete since maturation is halted. The regulatory imbalances 
may be the key to this derangement of the angiogenic process in tumours. The 
maturation would thus be inhibited at a primitive stage characterised by leaky vessel 
walls. Tsujii (1998) (working on in vitro model systems involving co-culture of 
endothelial cells with colon carcinoma cells) demonstrated that cyclo-oxygenase (a 
key enzyme required for the conversion of arachidonic acid to prostaglandins) plays 
an important role in the promotion of tumour related angiogenesis. The latter was 
inhibited by the application of non-steroidal anti-inflammatory compounds. 
Neo-vascularisation will usually herald the onset of symptoms and tumours may then 
become clinically detectable yet it is at this stage that tumours become less 
accessible to chemotherapy (Folkman J, 1995). The tumours possess an increased 
interstitial pressure from the leaky tumour vessels and the absence of intra-tumour 
lymphatic drainage. Thus vascular compression and eventually central necrosis 
ensue. Chemotherapeutic agents are unable to penetrate the tumour, partly for this 
reason.
Growth and metastases of tumours are known to be dependent on neo- 
vascularisation for several reasons. A high degree of tumour vascularisation with
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newly formed leaky vessels increases the chance for tumour cells to enter the 
circulatory system and metastasise (Folkman J, 1995). At the cellular level, neo- 
vascularisation augments tumour growth through a “perfusion” effect which allows 
metabolic exchange and a “paracrine" effect which supplies growth factors (Folkman 
J, 1971; Shalaby F et al, 1995). Perfusion is more efficient than diffusion in allowing 
metabolite and catabolite exchange in crowded tissue.
The angiogenic / tumourigenic effects of ET-1 could be mediated through the known 
mechanism of VEGF stimulation and enhanced endothelial mitogenesis in the 
existing tumour or vasculature. As mentioned earlier, selective ETA receptor 
inhibition in vivo resulted in reduced angiogenesis as measured by lower 
microvessel densities (Bhargava S et al, 2005). Wulfing (2004) observed a 
significant positive correlation between microvessel density and ET expression. 
Moreover, expression of VEGF was found more often in tumours with over­
expression of ET and its receptors. In ovarian cancer, ET-1 stimulated VEGF 
production through the ETA receptor and selective inhibition of this receptor 
significantly impaired the angiogenic response (Salani D et al, 2000)
Inhibition of VEGF has shown potent anti-tumour effects in in vivo animal models 
(Millauer et al, 1996). Thus ET-1 antagonists would play their anti tumour role as 
both anti-angiogenic and anti-mitogenic agents.
A number of anti-angiogenic therapies are proving effective in combating solid 
tumours. The focus of the therapies has comprised inhibiting positive angiogenesis 
regulators, enhancing negative ones or directly targeting tumour endothelial cells. 
The latter technique has proven effectiveness as demonstrated by Huang et al 
(1997) who demonstrated complete tumour regression of neuroblastoma xenografts 
in athymic mice. Similarly, Pipili-Synetos et al( 1995), working on the in vivo model of
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angiogenesis of the chick chorioallantoic membrane (CAM) and the model of growth 
and metastasis in the Lewis Lung carcinoma in mice, obtained results suggesting 
that angiogenesis inhibitors (isosorbide 5-mononitrate and isosorbide dinitrate) 
inhibited tumour growth and metastasis. Furthermore, in rodents, anti-angiogenic 
therapy increases the delivery of chemotherapy to a tumour (Teicher et al, 1994). 
This is explained by the suggestion that anti-angiogenic factors unpack the mass of 
tumour cells (Folkman, 1995), thus lowering the tumour’s interstitial pressure. 
Recently, anti-VEGF agents have, indeed, improved prognosis in patients with 
metastatic colorectal cancer, when added to standard chemotherapy (Kabbinavar FF 
et al, 2006).
1.5.2 Endothelin-1 and its Role in Tumourogenesis
Raised levels of ET-1 in specimens of various cancers are well established. Patients 
with primary or metastatic colorectal and primary liver cancers are also known to 
have elevated plasma ET-1 levels (Shankar et al, 1996; Nakamuta et al, 1993). ET 
receptor density is also altered with ETA upregulated, as detected by 
autoradiography, in specimens of prostate, lung and colorectal cancers while ETB is 
downregulated (Ali et al, 2000a, Nelson J etal, 1995, Zhao et al, 1995).
There are several reports indicating correlation between ET-1 expression and 
prognosis in cancer. In breast cancer the expression of ET-1 and both its receptors 
correlated with acquisition of malignant potential (Wulfing P et al, 2003). Univariate 
analysis has shown that ET-1 expression, in addition to sex, nodal metastatic 
involvement and stage, were significant predictors of poor survival and disease free 
survival outcome figures in non-small cell lung carcinoma (Boldrini et al, 2005). In 
colorectal cancer, a Cox regression model identified age, advanced stage and
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plasma big ET-1 levels as independent variables of significant prognostic value for 
overall survival (Arun et al, 2004).
Immunohistochemistry has shown that ET-1 is over-expressed in specimens of 
colorectal (Asham et al, 1997) hepatocellular (Kar et al, 1995) and prostate cancer 
(Nelson et al, 1996). A study conducted in our centre has also shown that colorectal 
cancer patients, with or without liver metastases, have elevated plasma levels of ET- 
1 (Shankar A et al, 1998). This is in agreement with studies on patients with 
hepatocellular cancer (Nakamuta et al, 1993). Also of interest is the finding that ETA 
receptors are upregulated in ovarian (Bagnato et al, 1999), colorectal (Ali H et al, 
2000a), lung (Zhao et al, 1995) and meningioma / glioma (Harland et al, 1998) 
suggesting that autocrine or paracrine ET-1 loops contribute to cancer growth and 
progression (Shichiri et al, 1991; Moraitis et al, 1997). The frequent concomitant 
downregulation of ETB receptors in the same cancer types (Nelson J et al, 1996), 
suggests that ETB is not used for any cancer associated signals or even its apparent 
loss may remove some as yet unidentified inhibitory loop.
In vitro, several cancer cell lines have demonstrated proliferation in response to 
exogenous ET-1. The cell lines include colonic, ovarian, and meningioma (Kitagawa 
et al, 1994). This effect was reversed on further addition of an ETA receptor 
antagonist as is also the case in pancreatic cancer cell lines (Bhargava et al, 2005). 
Ovarian cancer cell lines produce ET-1 and possess ETA receptors (Bagnato et al, 
1997). Moraitis (1997) working on two ovarian cancer cell lines, further found that 
addition of exogenous ET resulted in specific dose-dependent increases in cell 
number for ET-1 and ET-2 but not for ET-3. In the presence and absence of the 
exogenous peptides, the addition of BQ-123 reduced the cell number. This result is 
consistent with ET-1 acting via ETA receptors as a positive mitogen. Downstream
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events which propagate the mitogenic effect on ovarian cancer cells include EGFR 
transactivation and MAPK (Bagnato et al, 1999). Overall the known ET-1 positive 
mitogenic effects are not restricted to endothelial cells but also affect fibroblasts and 
cancer cells (Kusuhara etal, 1989; 1990).
Specifically in CRC, my field of research, the application of an ETA antagonist 
reduced cell growth in at least one human colorectal cell line (Ali et al, 2000 b). A 
pilot study using a syngeneic rat model of liver metastases demonstrated that the 
intraportal administration of the ETA specific antagonist, BQ-123, shortly after tumour 
cells were inoculated via the same route, resulted in significant reduction in tumour 
load (Asham et al, 1997). These results may be due to the inhibition of the mitogenic 
effect of ET-1 but there is strong evidence for the anti-angiogenic effect 
complimenting the former if not instigating it.
1.6 Colorectal Cancer
Colorectal cancer is the second commonest cause of cancer death comprising 10% 
of all cancer deaths in the UK. In England and Wales there are 17,000 deaths each 
year attributed to colorectal cancer (mortality stats: reviews of the register general on 
deaths by cause, sex and age in England & Wales1993 (revised 1994); Vukasin AP 
et al, 1990; Cancer Research UK 2005 http://info.cancerresearchuk.org/cancerstats 
/types/bowel/incidence ). Of the annual incidence of 30,000 new cases per year IQ-
12,000 are rectal cancers (Cancer Research Campaign. Factsheet 18.1 1993, 2005 
Cancer Research UK http://info.cancerresearchuk.org/cancerstats 
/types/bowel/incidence). This distinction is important for deciding on neoadjuvant 
and adjuvant therapy and for the sake of comparisons between outcomes. Within 
the colon about 50% of cancers arise in the left side and 25% in the right (Cancer
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Research UK 2005 http://info.cancerresearchuk.org/cancerstats /types/bowel).
The aetiology of colorectal cancer is multifactorial. It is now accepted that there is an 
inherited and sporadic from. Approximately 5% of colorectal cancer cases diagnosed 
are attributable to an underlying hereditary colorectal cancer syndrome (Kwak EL et 
al, 2007). These include hereditary non-polyposis colorectal cancer (HNPCC) which 
is inherited in an autosomal dominant fashion. It arises due to mutations in mismatch 
repair genes, whose role is to repair mistakes in base pair matching during DNA 
replication. The clinical diagnosis of HNPCC families is based on the Amsterdam 
criteria I and II of the International Collaborative Group on HNPCC (ICG-HNPCC) 
(Vasen HFA et al, 1999). Familial adenomatous polyposis (FAP) is less common 
than HNPCC but is associated with a 100% risk of developing colorectal cancer. 
Again, it is inherited in an autosomal dominant fashion and is due to a mutation in 
the tumour suppressor adenomatous polyposis coli (APC) gene on chromosome 5q 
(Wu JS et al, 1998; Potter JD 1999). Other less common inherited colorectal cancers 
occur in patients with the autosomal dominant Peutz-Jeghers syndrome and juvenile 
poylposis.
Genetic aspects to the development of sporadic colorectal cancer tend to be similar 
to those found in FAP cancers and comprise mutations of the APC, K-ras and p53 
genes. The latter mutations are found in more than 60% of all adenomas and 
carcinomas (Powell SM et al, 1992; Vogelstein B et al, 1988; Scott N et al, 1993; 
Kikuchi-Yanoshita et al, 1992). These mutations drive the adenoma carcinoma 
sequence. The remaining sporadic cancers are genetically closer to HNPCCs. There 
has been evidence that dietary factors such as lack of fibre and vegetables, and 
excess of animal fats are associated with an increased risk of colorectal cancer for 
sometime now (Burkitt, 1971; Modan et al, 1975; Bjelke, 1973). There has also
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been recent, reserved, enthusiasm about the inhibitory effect of COX-2 inhibitors on 
colonic adenoma and adenomatous polyp progression (Bertagnolli MM et al, 2006; 
Arber N et al, 2006).
Recent advances in colorectal cancer have focused on combinations of 
monoclonal therapies and chemotherapy which have resulted in better clinical 
outcomes than with either modality alone (Wadler S, 2007). These include the 
incorporation of cetuximab (blocks EGF binding to the EGFR) and the 
monoclonal antibody bevacizumab (anti VEGF-A) into the various 
chemotherapy regimes. These combinations show increased response rates 
and overall survival (Iqbal S et al, 2004; Giantonio et al, 2006; Kabbinavar FF 
et al, 2006).
1.7 Liver Metastases
1.7.1 Summary
Tumour metastasis is the leading cause of death in cancer patients. The distribution 
pattern of metastases can be predicted in part by the pattern of regional venous 
drainage. Most metastases develop in the first capillary bed encountered after 
discharge from the primary tumour. However, tumours also metastasise to distant 
locations that are not predictable based on blood flow patterns. The high proportion 
of bone metastases in breast, prostate and lung cancers are examples of selective 
homing of tumour cells to a specific organ.
The liver is often the first site of colorectal metastatic disease and may be the only 
site of spread in as many as 30-40% of patients with advanced disease (Weiss et al, 
1986). The predilection for metastases to develop in the liver is partly due to the fact 
that the liver receives the portal drainage from the gastrointestinal tract via the
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mesenteric veins. In several experimental tumour models of liver metastasis, 
metastatic cells first implant in the portal endothelium (Barberaguillem E et al, 1989). 
These then break off into a portal radical and re-seed close to the initial lesion . Such 
satellite formation close to a large liver metastasis is common with secondary 
tumours of the liver (August DA et al, 1985).
For unexplained reasons the right lobe of the liver is more likely to develop 
metastases than the left lobe (Holbrook RF et al, 1995). Macroscopically these 
metastases are paler in colour than surrounding normal tissue. They enlarge by 
concentric growth and may attain a large size occupying most of the liver.
Liver metastases may be found in as many as 35% of patients undergoing resection 
of a colorectal tumour and another 8-30% will subsequently prove to have liver 
involvement. Furthermore, 40-50% of patients die within 5 years of an apparently 
curative resection and the liver is the most frequent site of relapse (Scheele J et al, 
1990; Gordon NLM et al, 1993; Stangl R et al, 1994; Jatzko etal, 1995). 25% of 
those who develop recurrences have them confined to the liver and therefore may 
be candidates for surgical resection (Adson MA, 1987). Unfortunately only 5% of all 
patients with colorectal cancer will ultimately benefit from such intervention (Wagner 
JS et al, 1984). This does, however, translate into 1000 patients treated each year in 
the UK.
Patients with liver metastases present in the late stages unless detected at the time 
of the primary cancer or are in a surveillance programme. The symptoms may be 
weight loss, upper abdominal discomfort and malaise. Evidence of liver failure such 
as ascites and jaundice are poor prognostic markers.
Inhibition of invasion constitutes a new class of targets for chemo-prevention. 
Intervention could commence between the period of tumour proliferation and the
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onset of invasion, preventing the series of events leading to metastasis.
1.7.2 Detection and Imaging of Liver Metastases
The extent of liver involvement by metastases is an important survival determinant 
(Wagner JS et al, 1984) and, therefore, accurate staging of liver metastases 
provides a guide to the potential success of surgery. Several staging systems have 
been proposed (Gennari et al, 1986; Gayowski et al, 1994). The system modified 
from the International Union Against Cancer (UICC) and The American Joint 
Committee on Cancer (AJCC) recommendations for primary hepatobiliary tumours is 
in popular use. It incorporates tumour size, tumour distribution, number of 
metastases and extent of extra-hepatic disease (table 1.1).
Stage 5 year survival
I -  unilobar solitary tumours of any size 61%
II -  unilobar multiple tumours < 2cm without nodal 61%
disease
III -  unilobar disease with multiple lesions>2cm 28%
IVa -  bilobar lesions 20%
IVb -  bilobar lesions with nodal disease or 0%
extrahepatic disease
Table 1.1 - The staging system modified from the International Union Against Cancer (UICC) and The 
American Joint Committee on Cancer (AJCC) recommendations for primary hepatobiliary tumours 
with predicted 5-year survival.
The identification of spread helps to target treatment for those with confined disease 
and provides valuable prognostic information to all patients with colorectal cancer. 
The most widely used imaging technique is a contrast CT scan of the abdomen with
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detection rates for hepatic metastases of 68-91% (70% detection for lesions >1cm). 
An alternative to the transabdominal ultrasonography approach is intra-operative 
ultrasound examination (IOUS). IOUS may detect small lesions (<5mm) and other 
lesions indicating extra hepatic involvement, such as the porta hepatis lymph nodes, 
which may be difficult to visualise percutaneously (Ravikumar TS, 1996, Kruskal JB 
etal, 1996).
Early experience with laparoscopic ultrasonography suggests it can provide valuable 
staging information which may alter management (John TJ et al, 1994). The 
combination of a staging laparoscopy and laparoscopic ultrasound improve the 
selection of candidates for curative resection (Foley EF et al, 1998).
A recent meta-analysis of various imaging modalities for detection of colorectal 
metastases showed that F-18 fluorodeoxyglucose (FDG) PET had significantly 
higher sensitivity on a per patient basis but not on a per lesion basis compared with 
other modalities. Sensitivity estimates for MRI imaging with contrast agent were 
significantly superior to those for helical CT scan with 45 g of iodine or less (Bipat S 
et al, 2005). PET may still miss small hepatic lesions and its performance is affected 
by recent or current administration of chemotherapy. The list of imaging 
investigations used for diagnosing liver metastases is outlined in table 1.2. The colon 
should be fully examined to exclude recurrence or metachronous lesions. Also, the 
chest needs to be imaged for pulmonary deposits.
1.7.3 Current Management of Colorectal Liver Metastases - Surgery
Patients with untreated liver metastases generally have a poor prognosis, the 
median survival being less than 12 months (Bengtsson G et al, 1981; Lahr CJ et al, 
1983) and none survive five years. However, survival from time of diagnosis is
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Imaging Modality References
CT Ward 1989
Transabdominal ultrasound Ward 1989
Intra-operative ultrasound Charnley 1991; Hagspiel 1995
Laparoscopic ultrasound John 1994; Foley 1998
FDG-PET Bipat 2005
PET / CT / Spiral CT Votrubova J 2006
MRI Bipat 2005
Hepatic flow scinitigraphy and duplex 
colour ultrasound (for calculation of 
hepatic perfusion index)
Leveson 1985; Leen 1991
Table 1.2 -  Imaging investigations used in the diagnosis of colorectal liver metastases.
longer in patients with solitary lesions than in those with more widespread 
involvement (Rougier P etal, 1995). Several large series have reported five 
year survival ranging from 25% to 44% following resection of colorectal liver 
metastases (Cady B etal, 1991; Fong et al, 1999; Choti MA etal, 1999). A 
randomised study assessing outcome following resection compared with 
other treatment modalities is not likely to be undertaken.
Management of all patients with colorectal cancer should be the responsibility 
of colorectal cancer multidisciplinary teams. More recent data reports lower 
operative mortality after resection of colorectal liver metastases than that 
reported in previous decades (Scheele J et al, 1995; Stangl R et al, 1994; 
Cady B etal, 1991; Choti MA etal, 1999; Fong Y etal, 1997). No doubt, the 
reason for this is mutlifactorial but a volume effect on outcome has been 
shown by several recent studies (Dimick JB et al, 2003).
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Resection of hepatic metastases from colorectal cancer has been shown to 
offer the best chance of long-term survival (Scheele J et al, 1995). 
Unfortunately the majority of patients with colorectal hepatic metastases are 
not suitable for resection and therefore specific criteria should be used to 
select those who may benefit from such intervention. There still remains some 
controversy amongst clinicians about which patients are most suitable for liver 
resection and which would be better treated by non-surgical means.
In 1963 Woodington and Waugh published their experience with resection of 
colorectal liver metastases at the Mayo Clinic and demonstrated that a 20% 
5-year survival was possible in selected patients (Woodington GF et al,
1963); these results were confirmed by others who reported their experience
of liver resection for metastases from a variety of gastrointestinal primary 
tumours (Flanagan L et al, 1967). Although only 7-10% of all patients with
colorectal metastases are likely to benefit from hepatic resection, the 
frequency of this condition means that in the US approximately 5000 patients 
each year might be suitable for resection of liver metastases (Steele G et al, 
1991); extrapolated to the UK this suggests that up to 1000 patients each 
year might be treated in this way with benefit. Attempts to increase resection 
rates with neo-adjuvant (pre-treatment) chemotherapy have shown promise 
with a 14% increase in resectability reported in one study (Adam R et al, 
2001). Neo-adjuvant chemotherapy has been used to convert unresectable 
tumours to resectable ones using 5-FU, folinic acid and oxaliplatin.
Concerns about the remaining liver reserve after resection have led to the use 
of preoperative portal vein embolisation to increase the volume of the residual 
liver (Farges O et al, 2003). Another approach has been to plan a two stage
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hepatic resection in which the first stage is a non-curative resection or 
ablation and after subsequent hypertrophy the residual tumour is excised 
(Adam R et al, 2000; Neeleman N et al, 1996).
The two most important features of a tumour that influence patient survival in 
untreated liver metastases are extent of hepatic involvement at the time of diagnosis 
and the grade of the primary tumour. Multivariate analysis has not shown a 
consistent result regarding the relevance of the number of lesions on long term 
survival (Scheele J etal, 1995; Fong Y etal, 1997; Fong Y etal, 1999; Hughes KS 
et al, 1986; Schindl M et al, 2005).
It is, therefore, important to define the acceptable residual functioning volume. 
Acceptable residual liver volume is thought to be a third of the standard liver volume 
or the equivalent of two liver segments (Garden OJ et al, 2006).
Multivariate analysis of various prognostic factors provides a valuable guide to 
patient selection for hepatic resection and may prevent unnecessary surgery in 
patients unlikely to derive benefit from the latter (table 1.3).
Tumours that have the capacity to invade and metastasise to lymphatics are likely to 
be more aggressive than those without this potential. They may conceivably by-pass 
the liver, by spreading to pre-aortic lymph nodes, and beyond to the thoracic duct 
and systemic circulation. Although there may be a correlation between primary 
tumour stage and survival the relationship is not strong enough to preclude liver 
resection for patients with more advanced primary tumours. Despite this, there is 
again no consensus view on the correlation between stage of primary tumour and 
prognosis in published data (Scheele J et al, 1995; Nordlinger et al, 1992; Jatzko et 
al, 1995; Gayowski TJ et al, 1994).
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Distribution of metastases
Adequacy of resection margins
Gayowski 1994; Little 1987
Registry of Hepatic Metastases; 
Hughes 1988; Little 1987
Formal resection or ennucleation Hughes 1988; Scheele1995; 
Jatzko1995, Lise 1990
Age of patient Fong 1995
Synchronous vs metachronous Hughes1988; Nordlinger from his
resection book; Lise 1990
Presence of extra-hepatic disease Rosen 1992;
Nordlinger from his book
Tumour stage and grade Jatzko 1995; 
Gayowski 1994
Table 1.3 -  factors influencing survival following resection of liver metastases 
Survival following resection. The reported overall 5-year survival rates following 
hepatic resection of colorectal liver metastases range from 16-50% (Scheele J et al, 
1995; Jatzko JR et al, 1995; Fong Y etal, 1999; Ruers & Bleichrodt, 2002)). Studies 
of the natural history of untreated liver metastases reveal that a minority of patients 
with limited disease may live for long periods without treatment. Benefit following 
resection of liver metastases may be gauged best by comparing survival after 
resection with survival in this group of patients (Wagner JS et al, 1984). Even though 
some of these patients have “favourable” tumour biology, possibly allowing 
prolonged survival without treatment, long-term survival beyond 5 years is rare 
without liver resection (Wagner JS et al, 1984). This contrasts to patients undergoing 
hepatic resection where a survival plateau is noted about 5 years after resection 
(Adson MA, 1987; Steele G et al, 1989); the surviving patients subsequently have a 
life expectancy similar to that of a matched non-cancer cohort (Adson MA, 1987). 
Repeat resection also seems to provide equal benefit to the first liver resection
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(Antoniou A et al, 2007; Suzuki et al, 2001).
1.7.4 Other Therapies
Chemotherapy. Most patients with liver metastases are not suitable for resection 
and undergo palliative chemotherapy. Others receive adjuvant therapy and a smaller 
proportion receives neoadjuvant therapy aiming to down-stage unresectable 
tumours to resectable ones. Liver metastases receive up to 95% of their blood 
supply via the hepatic artery. Therefore hepatic arterial chemotherapy, through its 
locoregional effect, produces better response rate in patients with colorectal liver 
metastases. Some studies showed that this resulted in improved survival (Martin et 
al, 1990) and quality of life (Allen Mersh et al, 1994).
It is not possible to cure liver metastases with chemotherapy but the latter can 
prolong survival and should be considered in all patients not suitable for surgery 
(Scheithauer W et al, 1993; Simmonds PC, 2000; Jonker DJ et al, 2000). The 
chemotherapy may be administered systemically or via the hepatic artery or portal 
vein. The most commonly used systemic treatment, 5-fluorouracil (5-FU), inhibits 
thymidylate synthase and results in a tumour response in 5-18% of cases (Rougier P 
et al. In: Nordlinger B 1992). Newer agents such as irinotecan (topoisomerase I 
inhibitor) have shown improved 1-year survival compared with standard 5-FU 
regimen (Rougier P et al, 1998). The National Institute of Clinical Excellence (NICE) 
recommends the use of oxaliplatin-based regimens as first line therapy for all 
patients with non-resectable disease, and irinotecan based regimens for second line 
therapy after failure of first line treatment (Douillard JY et al, 2000; Giacchetti S et al, 
2000).
Neoadjuvant chemotherapy has been used to convert unresectable tumours to
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respectable ones using 5-FU, folinic acid and oxaliplatinum. A conversion rate from 
unresectable to resectable of 38% and a 3-year survival rate of 55% were reported 
(Bismuth H e ta l, 1996; Giacchetti S et al, 1999).
Adjuvant chemotherapy following liver resection uses 5-FU and folinic acid given 
systemically as a continuous infusion or a bolus. Two randomised studies show no 
difference in long term survival following hepatic artery infusion (HAI) (Rudroff C et 
al, 1999; Lorenz M etal, 1998). A much larger randomised trial comparing adjuvant 
HAI plus systemic chemotherapy versus adjuvant systemic chemotherapy in a total 
of 156 patients found that the former group had a significantly higher 2-year disease- 
free survival (Kemeny N et al, 1999).
Ablative therapies. The precise role of ablative therapy for hepatic metastases 
remains unclear. The CLOCC trial should help clarify this issue 
(http://www.eortc.be/protoc/Details.asp7ProtocoN40004). For those who decline 
surgery, have associated co-morbidities that preclude resection or have treatable 
extrahepatic disease ablative therapy may be indicated. There may also be a role for 
ablative therapy in patients whose tumours have been downstaged but remain non- 
resectable (Oshowa A et al, 2003; Jansen MC et al, 2005; Elias D et al, 2003;
Solbiati L et al, 2001). Resection combined with radiofrequency ablation (RFA) 
provides a surgical option for those with unresectable liver metastases and may 
prolong survival (Pawlik TM et al, 2003). RFA has also been shown to be effective 
on its own in the treatment of small liver metastases (Abitabile P et al, 2006) with 
80% 2 year survival.
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1.8 Aims
This project aimed to investigate:
1. The effect of ET-1 and its receptor antagonists on colonic cancer cell lines.
a. a mechanism for this action was sought.
b. ET receptor activation.
2. The ET receptor profile in human colorectal liver metastases tissue.
3. The in vivo effect of an oral ETA receptor antagonist on CRC liver metastases 
in an animal model.
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CHAPTER II
Mechanisms of Endothelin-1 Stimulated Proliferation in
Cancer Cells
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Aims
This chapter investigates the production of ET-1 and mechanisms of ET-1- 
stimulated proliferation in cancer cell lines. As described in the introduction 
ET-1 promotes a mitogenic stimulus in vitro in a number of cancer cell lines.
In the majority of studies the mitogenic signal is transmitted through the ETA 
receptor.
2.1 Introduction
Endothelin-1 (ET-1), a 21 amino acid vasoactive peptide (Yanagisawa e ta l, 1988), 
is a member of a family of three endothelins (Inoue et al, 1989). Its actions are 
mediated via two G protein-coupled receptor subtypes, ETA and ETB (Arai et al,
1990; Sakurai et al, 1990). ET-1 stimulates growth of smooth muscle (Komuro et al,
1988), fibroblasts (Yamashita et al, 1992) and several human cancer cell lines. The 
latter include ovarian (Bagnato A et al, 1999), prostatic (Nelson J et al, 1996), 
meningioma (Kitagawa et al, 1994) and CRC (Ali H et al, 2000 b) cells. ETA receptor 
antagonists block the growth effect in human ovarian, prostatic and CRC cell lines. 
The present study investigates mechanisms of ET-1 induced growth and the roles of 
mitosis and apoptosis. Furthermore, the effect of G-protein inhibition on the ET-1 
mitogenic effect was studied.
Two human CRC cell lines and one rat fibrosarcoma cell line were used. The latter 
was chosen as it was used previously in an animal model of colorectal liver 
metastases. In the latter model, the role of ETA receptor antagonists in vivo was 
investigated and found to reduce tumour growth significantly (Asham E et al, 2001).
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2.2 Materials and Methods
2.2.1 Cell Culture
Two human colorectal cancer cell lines; SW620 (derived from a metastatic colorectal 
adenocarcinoma, ECACC, Salisbury, Wiltshire, UK) and LIM1215 (derived from an 
HNPCC cancer donated by Professor M. O’Hare, Ludwig Institute of Cancer 
Research, London, UK) and a rat fibrosarcoma cell line MC28 (originally donated by 
Professor S. Eccles, Institute of Cancer Research, Sutton, Surrey, UK) were used. 
The cells were routinely cultured at 37 °C in Dulbecco’s Modified Eagle Medium 
(DMEM) containing phenol red pH indicator. The medium was supplemented with 
10% foetal calf serum (FCS), L-glutamine (2mM), penicillin (100IU/ml) and 
streptomycin (100pg/ml) (all reagents bought from Imperial Laboratories, 
Basingstoke, Hants, UK). The cells were incubated until they reached 80-90% 
confluence. At this stage the cells were routinely disaggregated with trypsin (1 mg/ml 
in 0.02% EDTA (ethylenediaminetetraacetic acid) in PBS (phosphate buffered 
saline)), counted and either passaged or used for the experimental studies 
described below.
2.2.2 ET-1 Assays
On reaching confluence in 75cm3 flasks, the cells were disaggregated and seeded at 
a 1:3 split in FCS-containing medium. After 24 hours the cells were incubated in 
serum free medium (containing glutamine and antibiotics as described above). 
Supernatants were collected at 24 and 48 hours, spun down to exclude dead cells 
and debris then stored at -80°C. At the time of supernatant collection the adherent 
cell numbers were counted using a haemocytometer. ET-1 levels in the media were 
assayed using an ET-1 kit for an ELISA (Nycomed Amersham, Little Chalfont,
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Bucks., UK). The levels were expressed per ml of medium per 106 cells.
2.2.3 Growth Assays
Measurement of cell growth was based on changes in cell number. Responses to 
the addition of exogenous ET-1 (Sigma Laboratories, Poole, Dorset, UK) were 
investigated under serum-free (0% FCS) conditions. Cells were plated in 24 well 
plates at a concentration of 2.0 x 104 cells/ml/well in fully supplemented DMEM.
After 24 hours the cells were washed (PBS), and incubated in 1 ml/well of ET-1 (in 
concentrations ranging between 10~11 to 10‘7 M) in serum-free (0% FCS) medium. 
After 48 or 72 hours the cells were washed and growth stopped by the addition of 
10% formal saline at 4*C for at least 1 hour.
In the experiments where ET receptor antagonists were used, cells were seeded, as 
before, for 24 hours. Cells were washed in PBS and then exposed to ET-1 at its 
most effective dose (determined from the previous experiments for each cell line) as 
well as one of two ET receptor antagonists; A-127722 (Alexis Corporation, Bingham, 
Notts., UK), a selective ETA receptor antagonist (at concentrations of 10'11 to 10'7 M) 
or BQ-788 (Alexis Corporation), a selective ETB receptor antagonist (at a 
concentration of 10'8 M), for 48 or 72 hours. Cell growth was stopped by fixation with 
formal saline as above.
The effect of G-protein inhibition with pertussis toxin (PT) on ET-1 stimulated cell 
growth was assessed on LIM1215 and SW620 only. Cells were pre-treated for 6 
hours with PT then exposed to increasing doses of PT (0.1-100ng/ml)±ET-1 (10'8M) 
for 48 hours. Again cells were fixed in formal saline, as above.
Cell number was then determined by the methylene blue assay (Oliver MH et al,
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1989) and read as absorbance at 650nm. Briefly, the dye chelates in nucleic acids, 
therefore the larger the amount of nucleic acids (i.e the larger the cell number), the 
higher the absorbance values.
2.2.4 Immunohistochemistry
DNA replication (as a measure of proliferation) in cells grown in the presence of ET- 
1 and/or ETA receptor antagonist for 48 or 72 hours in 24 well plates was determined 
by immunohistochemistry. The protocol followed was described in the previous 
section, and concentrations used for ET-1 were10"8M for MC28, 10'9M for LIM1215 
and 10'7M for SW620 and the concentrations of A-127722 were 10'11M for MC28, 
10‘9M for LIM1215 and 10"7M for SW620. The labelling reagent, 5-bromo-2’- 
deoxyuridine (BrDU), (Dako Ltd., High Wycombe. Bucks, UK) which binds to 
replicating DNA, was diluted 1:1000 in serum free tissue culture medium. Medium 
from the cultured cells was replaced with medium containing BrDU and cells were 
incubated at 37°C for 6 hours. The labelling medium was then removed and the cells 
washed in phosphate buffered saline (PBS). The cells were fixed in acid-alcohol 
(90% ethanol, 5% acetic acid, 5% water) at room temperature for at least 30 
minutes. The wells were re-hydrated by washing in PBS and then incubated in 
reconstituted nuclease/anti-5-bromo 2’-deoxyuridine (Dako Ltd.) for 1 hour. After 
washing, the cells were incubated in peroxidase anti-mouse lgG2a for 30 minutes, 
washed again and incubated in 3,3’-diaminobenzidine tetrahydrochloride (DAB) for 5 
to 10 minutes. The proportion of cells stained with DAB was counted manually 
(approximately 6 fields per slip), under a microscope, by two independent observers. 
The stained cells were those in which replicating intracellular DNA had bound BrDU. 
Our own pilot studies demonstrated that less than 4 hours incubation with BrDU
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resulted in a very small proportion of stained cells, while incubations over 10-12 
hours resulted in the majority of cells stained. Therefore, optimum exposure was 
determined at 6-8 hours.
2.2.5 Flow Cytometry
Apoptotic cells were recognised by their ability to bind Annexin V on cell-membrane- 
exposed phosphatidyl serine. These cells were then identified by flow cytometry. 
Cells grown in DMEM and exposed to ET-1 and/or specific endothelin receptor 
antagonists were harvested with trypsin and washed once in Annexin V binding 
buffer (BD PharMingen, San Diego, CA, USA). The cells were re-suspended in 1ml 
HEPES Buffer and 5.5pl of Annexin V-FITC (BD PharMingen) was added. After 
incubation in the dark at room temperature for 20 minutes, 100pl of a 50pg/ml 
solution of Propidium Iodide (Sigma) was added to gate out the dead cells.
The cells were analysed by flow cytometry using a FACSCalibur (Becton Dickinson, 
San Jose, CA, USA) measuring Annexin-FITC fluorescence in the FL1 channel 
(530/30 bandpass filter) and Propidium Iodide in FL2 (585/42 bandpass filter).
20,000 events were collected. Apoptotic cells were defined as being Annexin 
positive but Propidium Iodide negative, while late apoptotic/necrotic cells were 
positive for both Annexin and Propidium iodide.
2.2.6 Statistical analysis
Analysis of all cell culture experiments was carried out using a 1-way ANOVA. If 
statistically significant, post-hoc analysis was undertaken. A one-way Dunnetts test, 
set at p<0.05 was used for ET-1 dose response experiments, and Tukeys honestly 
significant difference (HSD) test, also set at p<0.05, was used for all other analyses.
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Means of minimum 6 independent repeats for all experiments were analysed, unless 
stated otherwise. All graphical data are shown as means and standard deviations 
(SD). Immunocytochemical data are given as medians ± ranges; the Mann-Whitney 
test was used for analysis with significance set at 0.05.
2.3 Results
2.3.1 ET-1 Assay
The production of ET-1 by the rat fibrosarcoma cell line MC28 and the colorectal 
cancer cell lines SW620 and LIM1215 were measured in media conditioned for 24 
and 48 hours. The normal range for ET-1 is 0.2 to 0.7 fmol/ml cells in human EDTA 
plasma and the following results were corrected for this. MC28 cells produced ET-1 
to the value of 1.1 and 1.3 fmol/ml/106 cells at 24 and 48 hours respectively.
LIM1215 values were 21.3 and 22.6 fmol/ml/106 cells respectively. SW620 ET-1 
production measured 11.3 and 8.4 fmol/ml/106 cells respectively. The baseline 
reading for ET-1 amounts in medium only was 0.6 fmol/ml. Results were derived 
after pooling supernatant and cell numbers from 4 independent repeats. The assay 
was repeated once and a mean value derived.
2.3.2 Growth Assay
MC28 cells showed an increase in number of cells on addition of ET-1 (10'7-10'1°M). 
The biggest effect was seen at an ET-1 concentration of 10'8M with increases of 
16.8% and 21.5% at 48 hours and 72 hours respectively (figure 2.1). The selective 
ETA antagonist A127722 by itself did not influence cell growth at any concentration 
and neither did the selective ETB antagonist BQ-788. The stimulatory effect of ET-1 
(at the most effective growth-promoting concentration 10'8M) was reversed by the
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addition of the ETA receptor antagonist, A-127722, at a concentration of 10'11M 
(figure 2.4). No significant change was seen on addition of ET-1 and the ETB 
receptor antagonist, BQ-788 (table 2.1).
LIM1215 cell growth showed similar trends to MC28 cells. The maximal effect of ET- 
1 was at 10‘9M (figure 2.2) showing an increase of 11.1% and 14.4% at 48 and 72 
hours respectively. Neither antagonist by itself at any concentration had an effect on 
cell growth. Again the stimulatory effect of ET-1 (10'9M) was reversed by A-127722 
(figure 2.5). As previously, no effect was seen with BQ788. SW620 cell growth was 
augmented by ET-1 at concentrations of 10‘7-10'11M. This effect was maximal at 
10’7M showing increases of 14.1% and 38% at 48 and 72 hours respectively (figure 
2.3). A-127722 alone had a dose dependent inhibitory effect in its own right 
particularly at 10'7M (figure 2.7), but BQ788 did not. The stimulatory effect of ET-1 
(10‘7M) on SW620 cell growth was reversed by addition of A-127722 (figure 2.6). 
The maximal inhibition of growth was by 12.8% and 18.3% at 48 and 72 hours 
respectively, at an A-127722 concentration of 10'7 M. BQ788 was ineffective either 
way.
The mitogenic effect of ET-1 (10'8M) at 48 hours was significantly reduced to near 
control levels on pre-incubation of cells for 6 hours with the selective G-protein 
antagonist PT. at doses of 1-100ng/ml, PT inhibited ET-1 stimulated growth to near 
control levels in both cell lines (SW620 and LIM1215). Inhibition was significant with 
doses of PT above 0.1ng/ml (p<0.01) (figure 2.8).
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Figures 2.1-2.3: The effect of the addition of endothelin-1 (ET-1) on MC28 (figure 2.1), 
SW620 (figure 2.2) and LIM1215 (figure 2.3) cell growth at 48 and 72 hours of incubation. 
The cells were incubated in the presence of ET-1 (10-11 to 10"7M; x axis). Cell growth was 
measured using the methylene blue assay and read as absorbance (equivalent to cell 
number) at 650nm. The absolute absorbance values were then converted to ratios 
(experimental / control; control=1). The results are displayed as mean ratio (S.D) (y axis) and 
for comparison a line through the control value is shown. Statistically significant growth is 
shown as ☆ p<0.05 (1-way ANOVA, Dunnetts). The biggest effect on MC28 is seen at ET-1 
of 10'8 M and this concentration was used for further experiments. For SW620 the biggest 
effect was seen at ET-1 concentrations of 1(T7M, and for LIM1215 it was 10’9M. The data 
represents the mean (+SD) of 8 independent repeats.
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Figure 2.3 LIM1215
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1.4
1.3
☆
control
☆
&  □  48 hours
□  72 hours
2 0.8
0.7
0.6
ET-1 A
agent added
ET-1 & A
Figures 2.4-2.6: MC28 (figure 2.4), SW620 (figure 2.5) and LIM1215 (figure 2.6) cells were 
incubated in the presence of ET-1 (most effective concentration) ± ETA (A-127722, A) or ETB 
(not shown) receptor antagonists, or in the presence of ETA antagonist (A) alone (x axis). Cell 
growth was measured using the methylene blue assay and read as absorbance (equivalent 
to cell number) at 650nm. The absolute absorbance values were then converted to ratios 
(experimental / control; control=1). The results are displayed as mean ratio (S.D) (y axis) and 
for comparison a line through the control value is shown. On addition of a combination of ET- 
1 and ETa antagonist the increase in growth is reversed ( ^  p<0.05 1-way ANOVA, Tukeys 
HSD) in all three cell lines. For SW620 only (figure 2.5), the addition of the ETA antagonist by 
itself reduced growth significantly compared to control values ( p<0.05 Mann Whitney
test).The concentrations of ET-1 used were 10'8M, 10'7M and 10’9M for MC28, SW620 and 
LIM1215 respectively. The concentrations of ETA antagonist used were 10'11M for MC28 and 
LIM1215 and 10 7M for SW620.
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Figure 2.7 SW620
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Figure 2.7: The effect of the addition of the ETA selective antagonist A127722 on SW620 cell 
growth at 48 and 72 hours of incubation. The cells were incubated in the presence of 
A127722 (10~11 to 10_7M; x axis). Cell growth was measured using the methylene blue assay 
and read as absorbance (equivalent to cell number) at 650nm. The absolute absorbance 
values were then converted to ratios (experimental / control; control=1). The results are 
displayed as mean ratio (S.D) (y axis) and for comparison a line through the control value is 
shown. Statistically significant growth is shown as &  p<0.05 (1-way ANOVA, Dunnetts). 
There was dose dependent inhibition, maximal at 10 7M. The data represents the mean 
(+SD) of 8 independent experiments.
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Figure 2.8: Effect of G-protein inhibition with pertussis toxin (PT) on ET-1 stimulated cell 
growth. Cells were pre-treated for 6hrs with PT, then with increasing doses of PT (0.1- 
100ng/ml) ± ET-1 (10'8M) for48hrs. Cell growth was measured using the methylene blue 
assay and read as absorbance (equivalent to cell number) at 650nm. Data represents the 
mean ± SD of six independent experiments. LIM1215: p=0.003, SW620: p=0.002 (Tukeys 
HSD ). ^  Significant at p<0.05 on post-hoc analysis (Tukeys HSD).
2.3.3 Immunohistochemistry
All cell lines showed significant ET-1-induced increases in DNA proliferation. These 
increases were reversed on further addition of the selective ETA antagonist A-
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127722.
The proportion of MC28 cells that stained for BrDU (displaying active DNA 
replication) under control conditions was 51.7% (S.D. +/-3.3). On addition of ET-1 
the proportion became 64.3% (S.D. +/-1.3) (a 23% increase, p<0.01) and this 
returned to approximately baseline levels, 49.4% (S.D. +/-1.1), when the cells were 
incubated in both ET-1 and A-127722 (table 2.2).
LIM1215 cells followed the same trend. Under control conditions 42.1% (S.D. +/-2.1) 
of cells stained for BrDU, while 69.7% (S.D. +/-2.1) did so under the influence of ET- 
1 (67% increase, p<0.01). When ET-1 and A-127722 were added 38.3% (S.D. +/- 
3.6) of cells stained (table 2.2).
36.5% (S.D. +/-2.4) of SW620 cells stained for BrDU under control conditions. This 
percentage increased to 43.0% (S.D. +/-0.6) on addition of ET-1 (16% increase, 
p=0.015) and fell back to 37.4% (S.D. +/-2.3) on addition of both ET-1 and A-127722 
(table 2.2).
2.3.4 Flow Cytometry
Viable cells do not bind Annexin V-BIOTIN or propidium iodide (lower left quadrant). 
Early apoptotic cells with exposed phosphatidyl serine but intact cell membranes 
bind Annexin V-BIOTIN but exclude propidium iodide. Fluorescence from this 
population is displayed in the lower right quadrant. Necrotic or apoptotic cells in 
terminal stages will be both Annexin V-BIOTIN and propidium iodide positive and are 
displayed in the upper right quadrant. A small percentage of normal cell death 
should be expected in routine cultures of untreated cells.
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Figure 2.9 displays flow cytograms for MC28 cells. There were no significant 
changes in the number of cells undergoing apoptosis in the cells exposed to ET-1 
(b) as compared to controls (a). Furthermore, the combination of ET-1 and A-127722
Figure 2.9. Flow cytograms for MC28 cells. Viable cells are shown in the lower left-hand 
quadrant of the dot plots (LL). Early apoptotic cell fluorescence is reported in the lower right- 
hand quadrant (LR). Necrotic or apoptotic cells in terminal stages will be reported in the 
upper right-hand quadrant (UR).
The cells were incubated in DMEM (a), in the presence of 10'8 M ET-1 (b) or in the presence 
of 10'8M ET-1 and 10'11 M ETA antagonist, A-127722 (c). The percentage cells in the LR
R *  KD0909Q&004
FL1-H
quadrant were 1.88, 2.27 and 1.71 respectively. This experiment was repeated 10 times for 
MC28 cells. Similar results were observed in the other cell lines.
B
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(c) shows no change either. The results for all cell lines are displayed in table
2.3 and show similar results for LIM1215 and SW620.
2.4 Discussion
Endothelin-1 has mitogenic effects on several cancer cell lines including ovarian 
(Shichiri M et al, 1991; Bagnato A et a/,1999), prostatic (Nelson et al, 1996), 
meningioma (Kitagawa et al, 1994), epithelial carcinoma cell lines derived from 
human cervix and larynx (Harland S et al, 1998) and colorectal (Ali H et al, 2000 b). 
This chapter describes a proliferative effect on colorectal cancer and rat 
fibrosarcoma cell growth.
The cancer cell lines investigated, all secreted varying concentrations of ET-1 into 
their medium. The highest concentration was produced by LIM1215 cells and the 
lowest by MC28 cells. In contrast, the ET-1 plasma level in patients with colorectal 
cancer has been measured at about 4 pg/ml (Shankar A et al, 1998). This 
represents a 10,000 fold increase compared to ET-1 from cancer cell lines.
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However, ET-1 is thought to act in an autocrine or paracrine manner and, therefore, 
plasma levels do not necessarily give a true indication of action at the cellular level. 
The fact remains though, that plasma circulating ET-1 levels are in vast excess to 
those sufficient for cellular action.
In vitro, the biggest growth effect of ET-1 was seen on SW620 cells. Interestingly, 
only SW620 cells reacted to the addition of A-127722 alone. These results may be due to a 
relatively lower proportion of endogenous ET-1 binding to the receptors in SW620. 
Thus, the competitive exogenous ET-1 or A-127722 may have a more pronounced 
effect than on the other cell lines. Alternatively SW620 cells may have a larger 
density of ETA receptors compared to the other two cell lines investigated or that 
there are different subtypes of the ETA receptor with varying response intensities to 
the receptor antagonists.
The effect of ET-1 is mediated by the ETA receptors. This is demonstrated by the 
reversal of the ET-1 growth effect with the addition of ETA receptor antagonists. ETB 
receptor antagonists have no effect. The addition of exogenous ET-1 had a much 
greater effect on cell growth than endogenous ET-1 since the use of the ETA 
receptor antagonist, A-127722, had no inhibitory effect on endogenous ET-1 except 
when used on SW620 cells. These observations are supported by work on other 
cancer cell lines including prostate (Nelson et al, 1996) and ovarian (Kitagawa et al,
1994). However, there are reasonable suggestions that in both breast cancer 
(Rajeshkumar et al, 2005) and cutanous melanoma (Bagnato et al, 2004) the ETB 
receptor plays a more integral role in mitogenesis than ETA receptor.
Changes in cell numbers are a result of the interplay between apoptosis and mitosis. 
The increase in BrDU uptake suggests that ET-1 stimulates mitogenesis in the 
cancer cell lines. Radiolabelled thymidine incorporation studies performed by other
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workers have also shown an increase in proliferation. Bagnato (1997) working on 
human ovarian carcinoma cell lines and Kitagawa (1994) working on cultured human 
meningioma cells both showed dose dependent increases in DNA synthesis in the 
presence of ET-1. This increase, in both cell lines, was blocked by BQ-123, an ETA 
receptor antagonist. Measuring DNA replication using BrDU offers only a snapshot 
in time. However, preliminary measurements made after 8 hours of cell incubation 
with BrDU showed a similar result, while incubation for an hour was insufficient to 
show staining and 24 hour incubation resulted in the staining of all cells.
The flow cytometry data showed no changes in apoptosis after incubation with ET-1. 
However, ET-1 induced inhibition of apoptosis has been reported in endothelial cells 
via ETb receptors (Shichiri M et al, 1998) and in prostate cancer cells via the ETA 
receptor (Nelson J et al, 2005). Eberl and colleagues reported that the mixed 
endothelin receptor antagonist Bosentan promoted apoptosis in human (HT29 and 
SW480) and rat (PROb and REGb) colonic carcinoma cells in vitro (Eberl LP et al, 
2000b). The latter study focused on changes detected 24 hours after treatment. In 
our experience at such a time interval there was no significant increase in net cell 
number growth. We, therefore, concentrated on findings at 48 hours and longer.
The G-protein inhibitor PT inhibited the mitogenic effect of ET-1 at doses 1- 
100ng/ml. This suggests that the mitogenic effect in colorectal cancer cells is 
mediated by PT sensitive G-protein sub-units: Go or Gi. Our findings contrast with 
results in ovarian cancer cell lines which demonstrated that ET-1 stimulated DNA 
replication was not inhibited by pre-incubation with PT (Bagnato A et al, 1997). The 
ET-1 mitogenic action in ovarian cancer cells, therefore, appears to be mediated via 
different G-protein subunits. In addition the mitogenic effect of ET-1 on vascular 
smooth muscle cells, mediated through the transactivation of the EGFr, requires a
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pertussis toxin insensitive G-protein (del Bufalo D et al, 2002). However, stimulation 
of the ETa receptor with ET-1 results in receptor coupling with the PT sensitive Go a 
and Gi3 a-subunits, in addition to the PT insensitive G-proteins Gq/Gn (Iwasaki H et 
al, 1998).
ET-1 plays a critical role in tumourigenesis and Kim (2005) has shown that 
enhancement of the (3-Catenin signaling pathway activates the ET-1 gene (EDN1). 
The cell signalling pathways following activation are complex and involve G-protein 
phosphorylation of multiple pathways including phosphoinositide 3-kinase (PI3K) 
cascades which trigger calcium channels (Kawanabe Y et al, 2002; 2003). ET-1 
effects are also mediated partly by protein kinase C (PKC), phospholipase C (PLC) 
(Sugawara F et al, 1996; Bagnato A et al, 1997) and phospholipase D (PLD) (Robin 
P et al, 2005). Both of the cyclo-oxygenase -1 and -2 (COX-1 and COX-2) enzymes 
are involved in tumour progression by promoting tumour angiogenesis, proliferation, 
survival, invasion and metastasis in several solid tumours. ET-1 has been shown to 
induce COX-2 and related prostaglandin E2 release through the activation of the ETA 
receptor (Hughes AK et al, 1995). There is also a complex interaction between the 
mitogen activated protein kinase (MAPK) pathway and ET-1 signaling (Song et al, 
1996).
The pharmacological blocking of the ETA receptor appears to inhibit tumour 
progression and there is better understanding of the cellular ramifications of such an 
action.
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A.
MC28 Control ET-1 E/BQ
1 1.24 1.28
1 1.23 1.25
1 1.29 1.24
1 1.21 1.24
1 1.19 1.26
1 1.22 1.24
1 1.21 1.23
1 1.23 1.24
Mean 1 1.2275 1.2475
SD 0.0296 0.0158
B.
SW620 Control ET-1 E/BQ
1 1.29 1.23
1 1.35 1.25
1 1.33 1.26
1 1.28 1.26
1 1.36 1.29
1 1.33 1.38
1 1.32 1.41
1 1.33 1.36
Mean 1 1.32375 1.305
SD 0.0272 0.0682
C.
LIM1215 C ontro l ET-1 E/BQ
1 1.16 1.21
1 1.18 1.2
1 1.18 1.2
1 1.19 1.19
1 1.21 1.22
1 1.22 1.27
1 1.21 1.26
1 1.19 1.2
Mean 1 1.1925 1.21875
SD 0.0198 0.0299
Table 2.1. The effect of ET-1 and the selective ETB receptor antagonist, BQ-788 (BQ) at a 
concentration of 10'8M, on cell growth of MC28 (A) (ET-1 used at lO^M), SW620 (B) (ET-1 at 
10'7M), and LIM1215 (C) (ET-1 at 10‘9M) all after 48hrs agent exposure. Cell growth was 
measured using the methylene blue assay and read as absorbance (equivalent to cell 
number) at 650nm. The absolute absorbance values were then converted to ratios for ease of 
presentation (experimental / control; control=1) and the means and standard deviation (SD) 
calculated. Each result is the sum of 8 repeats.
63
Cells
Medians
(range)
MC28 SW620 LIM1215
Control 51.7 (+/-3.3J 36.5 (+/-2.4) 42.1 (+/-2.1)
+ ET-1 64.3 (+/-1.3) 43.0(+/-0.6) 69.7 (+/-2.1)
+ ET-1 
& A-127722
49.4 (+/-1.1) 37.4 (+/-2.3) 38.3 (+/-3.6)
Table 2.2. Percentage of cells positive for BrDU staining after incubation for 72 hours in 
DMEM alone (control), ET-1 or ET and ETA receptor antagonist, A-127722. Cells were 
visualised by indirect immunohistochemistry using DAB as chromogen and counted manually 
under the microscope. There was a significant increase in the proportion of MC28 cells 
binding BrDU on incubation in ET-1 (10'8M) compared to control (p<0.01, Mann Whitney). 
This was reversed on incubation in ET-1 (10'8M) and A-127722 (10'11M) (p<0.01). Similarly, 
for SW620. incubation in ET-1 (10'7M) resulted in a significant increase in the percentage of 
cells binding BrDU (p=0.01) which was reversed on addition of A-127722 (10'7M) (p=0.015). 
LIM1215 also bound more BrDU on incubation in ET-1 (10'9M) (p<0.01) and this increase 
was reversed on incubation in ET-1 and A-127722 (10'11M)(p<0.01). Experiments were run at 
least three times in quadriplicates. The Mann Whitney test was applied to the data 
throughout.
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Cells MC 28 SW 620 LIM 1215
C E E/A E E/A E E/A
repeat
1
1 0.76 0.66 0.46 2.5 0.31 1.09
repeat
2
1 0.76 0.69 0.76 2 4 8 0.46 1.45
repeat
3
1 0.73 0.99 1.33 1.57 0.43 0.43
repeat 
4 '
1 0.78 0 9 6 0.8 0 2 1 0.46 0.51
repeat
5
1 0.37 1.12 0.96 0.25 2.09 1.27
repeat
6
1 0 4 6 0.74 1.13 1.42 1.65 1
repeat
7
1 1.36 1.1 0.86 1.41 0.74 0.78
repeat
8
repeat
9
1
1
1.4
1.23
1.41
1.43
0.74
0.69
1.09
0.3
1.47
0.96
1.21
1.21
repeat
10
i 1 1.21 0.91 0.37 0.14
repeat
11
1.15 1.26
mean
S.D
p-value
0.906
0.369
>0.05
1.001
0.272
>0.05
0.841
0.290
>0.05
1.148 
0.858 
> 0 .05  |
0.952
0.639
>0.05
0.994
0.351
>0.05
Table 2.3. The proportion of apoptotic cells for MC28, SW620 and LIM1215 cells, as 
visualised by flow cytometry, is displayed. The cells incubated in DMEM only (control, C) 
were normalised to a value of 1. The proportion of cells exposed to ET-1 (E), and a 
combination of ET-1 and A-127722 (E/A) were then expressed as a proportion of 1. There 
were no significant changes in apoptosis in any of the 3 cell lines (p>0.05 for all experimental 
limbs, 1-way ANOVA, Tukeys HSD).
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CHAPTER III
Endothelin Receptor Expression in Colorectal Liver
Metastases
66
Aims
This study aims to establish whether or not the ET receptor profile in 
colorectal liver metastases differs from normal liver tissue and how it 
compares to previously detected receptor profiles in normal colon and primary 
colorectal cancer. If there is a detectable change in receptor profile liver 
metastases may respond differently to ET-1 compared to normal liver cells.
3.1 Introduction
Two main subtypes of ET receptor have been cloned from cDNA libraries, ETA and 
ETb (Sakurai T et al, 1992). ET-1 may act as a growth factor for colorectal as well as 
other cancer cells via one or both of its receptors, ETA and ETb 
The development of highly specific agonists and antagonists for these 
receptors has provided tools for studying the role of ET-1 in tumour 
vasculature and tumour growth. Radiotracer techniques used in a rat model 
demonstrated selective tumour vasoconstriction in response to a selective 
ETb receptor agonist. Autoradiography applied to the same model showed 
regions of intense specific ETB receptor binding scattered throughout the 
tumour mass (Bell KM et al, 1998; 1999). Autoradiography has also detected 
the presence of binding sites (putative receptors) for ET-1 in colorectal cancer 
specimens and normal colon tissue (Inagaki H et al, 1991 a; 1991b; 1992).
Ali (2000a) demonstrated the up-regulation of ETA receptors and down- 
regulation of ETB receptors in primary human colorectal cancer tissue. Here, 
we used in vitro receptor autoradiography to study the expression of
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endothelin receptor subtypes in human colorectal liver metastases and in 
adjacent normal liver. Micro-autoradiography has also been used in 
combination with immunohistochemistry to identify binding to specific cell 
types in slide-mounted tissues.
3.2 Materials and Methods
3.2.1 Tissue collection and preparation
Following approval from the local ethical committee, patients (n=7) 
undergoing liver resection for colorectal liver metastases were informed and 
consented for use of the specimens for our research purposes. At the 
operation, 1 cm3 samples of liver metastases (n=13) and adjacent normal 
liver tissue (n=13) (approximately 5cm away) were excised, and immediately 
cut into small sections, stored in 1ml cryotubes and preserved frozen in liquid 
nitrogen.
3.2.2 In vitro autoradiography
ET-1 receptors were identified as described previously (Dashwood M et al, 
1990). Briefly, 10pm frozen sections were cut on a cryostat, then thaw- 
mounted onto gelatinised microscope slides and air dried. These were either 
used immediately for experiments or stored at -70°C for future use.
The slide-mounted sections were incubated in 150pM [125I]ET-1 (specific 
activity 2000 Ci/mM) and non-specific binding was determined by co­
incubation of alternate slides in the presence of 500nM unlabelled ET-1. ET 
receptor subtypes were identified using 150pM [125I]-PD151242 for ETA
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receptors or [125I]-BQ3020 for ETb receptors, specific activity 2000Ci/mM for 
both (Amersham Pharmacia Biotech, Little Chalfont, Bucks., U.K.).
Autoradiographs generated on 3H Hyperfilm (Amersham Pharmacia Biotech, Little 
Chalfont, Bucks., U.K.) (figure 1) were semiquantified by densitometric analysis. 
High-resolution autoradiography was used to identify binding at the cellular level, 
where slides were coated with a nuclear emulsion (K-2, Ilford, Mobberly, Cheshire, 
U.K.).
For quantitative assessment images were digitised (Hewlett Packard scanner, Palo 
Alto, California, USA) and analysed by reading grey densities of the histograms in 
Adobe Photoshop. In this densitometric analysis, each cm3 was divided into 255 
points, each point given a comparative figure from 0 to 250 (0=black, 250=white), 
equivalent to disintegrations per minute. Means and standard deviations were 
calculated.
3.2.3 Double labelling
Radioligand binding to endothelial cells was confirmed on selected tissue 
sections by using a combination of immunohistochemical and 
autoradiographic techniques. Here, vascular endothelium was identified using 
PECAM (platelet endothelial cell adhesion molecule-1, CD31). Slides were 
incubated in primary antibody, anti-CD31 (diluted 1:200 in PBS pH 7.4, for 30 
minutes and indirect immunohistochemistry performed using the Vector 
alkaline phosphatase method (Vector Laboratories, Peterborough, Cambs,
UK), with vector red as the chromogen and counterstained with Mayer’s 
haematoxylin. After tissue processing and immunohistochemical staining, 
slides were transferred to buffer containing [125I]-ET-1, [125I]-PD151242 for
69
ETa receptor or [125I]-BQ3020 for ETB receptor binding as described 
previously. Sections were coated with nuclear emulsion and stored for 8 days 
at 4°C in light-proof boxes containing a dessicant. After processing the 
emulsion following the manufacturer’s instructions [125I]-ET-1 binding to 
endothelial cells was evident as an accumulation of dark grains overlying cells 
exhibiting positive PECAM immunoreactivity.
3.2.4 Statistical analysis
Analysis of the autoradiography data was carried out using the Wilcoxon 
signed rank test.
3.3 Results
3.3.1 In vitro Autoradiography
[125I]-ET-1 binding was identified in both normal liver and liver metastases 
sections. Tissue specimens from liver metastases displayed a significant 
reduction in ETb receptor binding ([125I]-BQ3020 binding) in tissue from liver 
metastases (64.6 x 103 gd [grey densities]/mm2 S.D. 6.9) compared to normal 
liver tissue (134.5 x 103 gd/mm2 S.D. 16.9) (p<0.0001). ETA receptor density 
([125I]_PD151242 binding) was not significantly altered in liver metastases 
(103.3 x 103 gd/mm2 S.D. 23.2) compared to normal liver tissue (116.7 x 103 
gd/mm2 S.D. 15.6) ( table 3.1 and figure 3.1).
Micro-autoradiographs, generated on emulsion, showed binding of [125I]-ET- 
1 to endothelial cells in the tumour tissue (figure 3.2).
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3.3.2 Double labelling
[125I]-ET-1 binding to vascular endothelial cells within the liver metastases 
section was confirmed using CD31 (figure 3.3).
Liver metastases Normal liver
Specimen
number
ETa 
Mean (SD) 
gdx1000/mm2
ETb 
Mean (SD) 
gd1000/mm2
ETa 
Mean (SD) 
gdx1000/mm2
ETb 
Mean (SD) 
gdxl 000/mm2
1 94.35 (25.06) 78.55 (14.36) 111.03 (27.84) 126.08 (29.1)
2 88.27 (20.92) 63.84(11.88) 127.87(15.8) 154.51 (15.1)
3 85.34(18.17) 75.85(18.21) 118.85(15.21) 151.19(26.77)
4 91.33 (22.43) 63.67 (25.29) 117.65(17.32) 111.26(14.95)
5 90.93 (25.01) 62.52 (21.25) 110.12(16.17) 111.78(14.64)
6 124.08 (25.03) 67.86(16.84) 120.86(18.4) 138.85(16.84)
7 123.3(25.68) 65.8 (8.68) 124.47(13.52) 133.48(16.92)
8 76.5 (25.83) 65.21 (15.7) 123.9(17.99) 159.69(17.47)
9 76.82 (32.04) 69.73(18.07) 134 (15.59) 156.41 (15.67)
10 84.19(23.75) 54.27 (6.11) 144.62(17.62) 113.28(19.2)
11 124 (32.81) 56.96 (6.47) 107.12 (23.22) 118.1 (20.82)
12 146.23 (25.57) 57.05 (7.53) 84.62 (19.32) 140.45 (20.45)
13 137.57 (27.92) 58.31 (7.56) 91.81 (21.72) 132.87(17.19)
Mean 103.3 64.59 116.69 134.46
SD 23.18 6.95 15.58 16.87
Table 3.1. Endothelin receptor expression in specimens of human liver metastases and 
normal liver, displayed in terms of grey density(gd) /mm2[equivalent to disintegrations per 
minute]. The values were derived by semiquantitative densitometry. ETA receptor density in 
liver metastases was not significantly changed (p>0.01 Wilcoxon signed rank test) from that 
in normal liver (103.30 S.D. 23.18 vs. 116.69 S.D. 15.58 respectively). ETB density, however, 
was significantly (p<0.01 Wilcoxon signed rank test) lower in liver metastases than in normal 
liver (64.59 S.D. 6.95 vs. 134.46 S.D. 16.87 respectively).
The data is displayed in graph form in Figure 3.1
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Figure 3.1
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ETa and ETB receptor binding on sections of liver metastases demonstrated by gross 
autoradiography. Semiquantitative densitometric analysis was performed on these films. 
Total ET binding sites are demonstrated on the left followed by ETA then ETB binding sites. 
Non-specific (non spec) binding was excluded from the total.
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Figure 3.3 [125IJ-ET-1 binding (dark grain accumulation) to sections of liver metastases 
using “double labelling”. There is dense binding to the endothelial cells (PECAM-positive, red 
stain) of tumour vessels.
3.4 Discussion
ET-1 has been implicated in the pathophysiology of a number of 
cardiovascular diseases, including coronary syndromes (Salomone O et al,
1995) systemic and pulmonary hypertension (Rubanyi GM et al, 1994) and 
atherosclerosis (Dashwood M et al, 1993; Zeiher AM et al, 1994). Studies 
using autoradiographic binding studies, demonstrated variations in endothelin 
receptor expression in human coronary vasculature and varicose veins 
(Dashwood M et al, 1998; Agu O etal, 2002). Radioligand binding combined 
with quantitative autoradiography can measure the affinity and localize the 
distribution of receptors (Inagaki etal, 1991a; 1991b; 1992).
73
Immunocytochemical localization using receptor subtype selective antisera 
has also been used successfully to map endothelin receptor distribution (Kuc 
R et al, 2004).
Tumour vasculature is morphologically and functionally abnormal (Carmeliet 
et al, 2000). Therefore, the vascular reactivity differs in tumours and there is 
potential for therapeutic selective modification of tumour blood flow (Brown et 
al, 1998). The vasoactive action of ET-1 is mediated primarily via the two ET- 
1 receptors. ETA receptors are mainly found on vascular smooth muscle cells 
and pericytes. These account for the profound vasoconstriction of ET-1. ETB 
receptors are found on contractile elements and endothelial cells and their 
activation can cause both vasoconstriction and vasodilatation (Davenport AP, 
2002).
Additional to vascular pathologies, ET-1 has also been strongly implicated in 
the pathophysiology of different cancers. It has been shown that ET-1 has 
mitogenic effects on prostatic (Nelson et al, 1996), ovarian (Moraitis et al, 
1997; Bagnato et al, 1999) and colorectal (Ali H et al, 2000b) cancer cells in 
vitro. Shankar (1998) demonstrated that there are elevated levels of ET-1 in 
the plasma of patients with CRC and colorectal cancer with liver metastases. 
Working on human pulmonary tumours, Zhao (1995) used a combination of 
autoradiography and immunocytochemistry to demonstrate that ET-1 binding 
sites are present on the blood vessels of the tumours. Similar results, using 
autoradiographic, saturation and competition studies, were obtained by 
Harland (1998) on human gliomas and meningiomas. In fact the latter group 
showed that the binding was predominantly to ETA receptors. ETA receptor 
expression is up-regulated in several types of cancer cell lines and in human
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colorectal cancer tissue. It has been suggested that the mitogenic stimulus of 
ET-1 is mediated predominantly via the ETA receptor (Shichiri M e ta l, 1991; 
Moraitis S etal, 1997). ET-1 stimulates proliferation and migration of 
endothelial cells through the ETB receptor (Morbidelli et al, 1995; Wren et al, 
1993; Goligorsky et al, 1999) and is a potent mitogen for vascular smooth 
muscle and tumour cells through the ETA receptor (Alberts et al, 1994; 
Bagnato etal, 1998). Nelson (1996), using autoradiography, and Bagnato 
(1999), using reverse transcription-PCR and Northern blot analysis, both 
demonstrated ET-1 production and endothelin receptor expression in 
prostatic and ovarian cancer cells respectively. In both cases an ETA receptor 
antagonist inhibited the ET-1-stimulated growth of cancer cells. Subsequently, 
Salani and colleagues (2000) localised ETA receptor expression to ovarian 
carcinoma cells and blood vessels whereas ETB receptors were confined to 
vascular endothelial cells. Autoradiographic binding studies confirmed that 
ovarian carcinoma cells functionally expressed ETA , and not ETB, receptors 
and that blood vessels co-expressed both receptors (Salani D et al, 2000).
Ali (2000a) performed similar work on human CRC cell lines and tissue. This 
group was able to show, using autoradiography, that both ETA and ETB 
receptors were expressed on the CRC cell lines although ET-1 proliferation 
signals were transmitted only via ETA receptors. Furthermore, there was an 
up-regulation of ETA receptors and down-regulation of ETB receptors in 
human CRC tissue. When these results are considered with those showing 
over-expression of ET-1 in CRC and colorectal liver metastases tissue 
(Asham E et al, 1997b), there appears a strong case for an autocrine / 
paracrine role for ET-1, acting via the ETA receptor, in CRC.
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This study further substantiates the work on colorectal cancer tissue (Ali H et 
al, 2000a). ET-1 was identified in both normal liver and liver metastases 
tissue (unpublished data from our laboratory). Using subtype specific agonists 
and antagonists, there are demonstrable endothelin receptors in normal and 
cancerous liver tissue. Therefore, the autocrine / paracrine loop may operate 
in colorectal liver metastasis. However, there is a reduction in ETb receptor 
density in the cancer tissue compared to controls. This is in agreement with 
findings in prostate cancer (Nelson J et al, 1996). However, in our view, since 
the metastatic tissue is colonic in origin, one must compare the endothelin 
receptor densitometry results with those obtained in colorectal cancer and in 
normal colon.
Ali (2000a) demonstrated that the ratio of ETA:ETB receptors in normal colon 
is 0.6:1 (129.2:207.0) and in primary colorectal cancer is 1.7:1 (206.0:122.4). 
The ratio in colorectal liver metastases is 1.6:1 (103.3:64.6). Thus, there is 
preservation of the ETa:ETb density ratio in metastatic tissue from colorectal 
cancer. The techniques used for the densitometry were identical in both 
studies. However, very strong conclusions about the significance of absolute 
densitometric significance can not be drawn unless one has access to cellular 
micro-autoradiography. Despite this difficulty, it is interesting that apart from 
the previously reported apparent over-expression of ETA receptors in primary 
CRC, there is a marked under-expression of ETB receptors both in primary 
and metastatic CRC tissue. It is possible that ET-1 contributes to the 
mitogenic drive stimulating CRC cell growth. The ETA:ETB ratio increase in 
both primary and metastatic cancer suggests that an imbalance in this ratio is 
an event that further drives cancer growth and/or is an established change
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“early” in tumourogenesis.
ETb receptor agonists have been shown to enhance the suppression of 
endothelial cell apoptosis by ET-1 (Shichiri M etal, 1998). We have already 
shown in chapter 2 that ET-1 produces its stimulatory effect on human CRC 
cell lines by potentiation of mitosis which is mediated to some degree by ETA 
receptors. It is plausible that ETb receptors also play a role in apoptotic or 
mitotic changes in CRC. A reduction in ETB receptor density may reduce 
apoptosis or increase mitosis.
Interestingly, it is also revealed that ET-1 binding sites are focused at the 
endothelial cells of the cancer tissue. Therefore, ETA receptors may play a 
role in neo-angiogenesis in the tumour, thus aiding mitogenesis further, as 
suggested by our group (Dawas K etal, 1999). However, there is evidence 
from ischaemic human muscle that ET-1 binding sites on microvessels may 
well be ETb receptors (Tsui JC et al, 2002).
It has been shown that human primary and metastatic CRC cells display a 
variation in the expression of endothelin receptors compared to controls. This, 
combined with the known ET production by CRC in vivo and in vitro, supports 
the autocrine / paracrine hypothesis. The ratio of ETA:ETB receptors changes 
from normal colon to colorectal cancer, and this change is preserved in liver 
metastases. The results discussed here raise the possibility of a therapeutic 
role for endothelin receptor antagonists in the management of colorectal liver 
metastases.
The next stage was to test this hypothesis in an animal model.
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CHAPTER IV
The effect of an oral ETA receptor antagonist on 
colorectal liver metastases in an animal model
78
Aims
This study aims to assess the effect of an oral ETa receptor antagonist, A- 
127722, on colorectal liver metastases in an animal model. The rats were 
inoculated with syngeneic MC28 rat sarcoma cells. These were previously 
described as having very similar properties to human colorectal cancer cell 
lines in vitro, in that their growth curves and dose response to ET-1 and ET 
receptor antagonists are the same (chapter 2).
4.1 Introduction
Blood vessels within colorectal liver metastases lack innervation and have an 
incomplete smooth muscle coat (Ashraf S et al, 1996). Thus the tumour blood 
vessels should not possess any significant neurogenic vasoconstrictor capability. 
This is useful for manipulation of the proportional delivery of chemotherapeutic 
agents to the tumour by selective vasoconstriction of normal hepatic vessels. Blood 
would then shunt into the tumour with a concomitant improvement in drug delivery. 
An animal model of colorectal liver metastases using syngeneic MC28 sarcoma in 
Hooded Lister rats is appropriate as a model of human liver metastases. It relies on 
the fact that the rat tumours have a similar blood vessel anatomical and 
physiological profile to human tumours, including hypovascularity and expression of 
ET-1 by the same cell types (Loizidou M et al, 1991, Loesch A et al, 1997; Ashraf S 
et al, 1997). Colorectal liver metastases develop by haematogenous spread through 
the portal circulation. A pilot study using the syngeneic rat model of liver metastases 
demonstrated that the intraportal administration of the ETA specific antagonist, BQ-
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123, shortly after tumour cells were inoculated via the same route, resulted in 
significant reduction in tumour load (Asham E et al, 2001). These results may be due 
to the inhibition of the mitogenic effect of ET-1 but there is strong evidence for the 
anti-angiogenic effect complimenting the former if not instigating it.
4.2 Methods
4.2.1 Cell Culture
MC28 cells were cultured as outlined in chapter 2. Once they reached 80-90 % 
confluence they were washed twice in PBS, disaggregated using trypsin/EDTA, then 
resuspended in Hanks medium to obtain a single cell suspension with a final 
concentration of 5 x 106 cells/ml.
4.2.2 Animals
Inbred male Lister Hooded rats weighing 180-300 g were used. The animals were 
housed in groups of two or three in standard cages and maintained on a routine rat 
pellet diet. Rats were divided into two groups: experimental (receiving ETa 
antagonist) and control (receiving medium without antagonist). Water (consumption 
per rat was worked out as roughly 40-45ml per day) was supplemented with the ETA 
antagonist, A-127722 (A-127722 (5mg/kg/day) was diluted [1mg in 1ml medium] in 
medium composed of 50% of 5% dextrose in a solution of 1M Eq. of NaOH, 30% 
propylene glycol and 20% ethanol), in the experimental limb and with the medium 
alone in the control limb. The supplementation was started 3 days prior to 
inoculation of cancer cells and continued for 17 consecutive days.
Twenty four hours prior to the termination of the experiment BrdU was injected into
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all rats intra-peritoneally (3mg/100g body weight). All experiments were carried out 
under a specific project license in accordance with the UK Animal (Scientific 
Procedures) Act 1986.
4.2.3 Inoculation of Cancer Cells
Anaesthesia was induced in the rats using 3% halothane and maintained on 1.5% 
halothane and 5L/min oxygen administered via a face mask. A midline laparotomy 
was performed, the caecum and terminal ileum were delivered through the wound 
and tributaries of the ileocolic vein were identified in the mesentery. With the aid of 
an operating microscope 1 x 106 MC28 cells (0.2 ml.) were injected into the vein 
using a 27 gauge needle. Pressure was applied at the puncture site on withdrawal of 
the needle to avoid backflow of blood. After ensuring satisfactory haemostasis the 
incision was closed using a continuous 3/0 Prolene® suture.
4.2.4 Tissue Specimens
Terminal anaesthesia was administered to the animals 2 weeks after surgery. The 
livers were excised, weighed and a note made of the number and size of 
metastases. The metastases were then dissected out and their total mass 
measured. The ratio of tumour to total liver mass was calculated (mass of 
metastases / total mass of liver).
4.3 Results
There were fourteen rats in each limb of the experiment. Three of the rats in the 
experimental arm and four in the control arm developed mesenteric deposits in the 
absence of any liver lesions and were excluded. Two of the rats in the experimental
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arm and six in the control arm died before the experiment was concluded.
Of the rats that grew liver metastases the T/L ratio in the experimental limb averaged
0.0196 (n=6) whereas in the control limb the ratio was 0.0074 (n=3).
There is no significant difference in the number, size or T/L ratio between the
experimental limb and controls (table 4.1).
A- LW Mets T/L Control LW Mets T/L
127722 No wt No. wt
1 1 1503 0 06 0004 1
2 25 18.2 1 28 0.07 2 2 11.79 0.05 0.004
3 5 15.14 025 0.017 3 11_ j 15.29 0 023 0 0015
4 4
5 5
6 6 2 16.87 0.05 0.003
1242 0.02 0.002 7
8 8
9 9
10 10
11 5 14.7 0.18 0.012 11
12 7 18.6 0.25 0.013 12
13 4 13.7 0.11 0008 13 0 19.16 0
14 18 13.39 1.13 0.084 14 0 17.34 0
Table 4.1. There were 14 rats in each limb of the experiment (A-127722 is the experimental 
group and the other is a control group). LW = total liver mass in grams, Mets wt = total mass 
of liver metastases (grams), T/L= ratio of tumour to total liver mass. No = number of 
metastases in liver.
4.4 Discussion
The results of this experiment did not yield much useful information. In this section, 
amongst other topics, I shall discuss the possible reasons for the unsuccessful 
outcome.
Efficacy studies in animal tumour models provide an early opportunity to collect 
preliminary information on toxicity (Arp LH, 1999). When screening and evaluating 
cytotoxic chemotherapeutic agents, efficacy studies usually include at least 1
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dosage level that causes severe toxicity and death. Pathologic evaluation in early 
efficacy studies may reveal major target organs, dosage/schedule relationships, 
pharmacokinetic/toxicity relationships, effects of formulation and route of 
administration, maximum tolerated dose, cause of death, and reversibility of 
changes in normal tissues. Intra-peritoneal formulations are frequently used to 
establish proof of concept for promising compounds (hits) from in vitro screens; 
however, these crude formulations may also induce intra-peritoneal inflammation 
and confound the interpretation of both efficacy and toxicity. Efficacy studies 
conducted in the later stages of drug discovery may be used to refine the dose and 
schedule proposed for phase I clinical trials. Efficacy studies in animal tumour 
models provide useful toxicologic data for screening potential drug candidates, 
optimising the therapeutic index, and designing both preclinical and clinical 
development programs.
An animal model using two syngeneic rat tumour lines has already shown that the 
ETb receptor has an important role to play in modification of tumour blood flow. The 
ETb agonist, IRL1620, caused a profound short-term reduction in blood flow in the 
tumour in the face of an increase in mean arterial blood pressure (Cemazar M et al, 
2005; Bell et al, 1995; 1999). Receptor binding studies also revealed the existence 
of both ETa and ETB receptors in the P22 tumour studied and that ETA receptors 
were more abundant than ETB receptors.
However, in a rat breast tumour model treatment of animals with ET-1 resulted in 
increased tumour blood flow compared to normal breast tissue in normal rats. This 
increase was attenuated by pre treatment with the ETB receptor antagonist BQ-788 
(Rai A et al, 2003).The pilot study that pre dated this experiment showed a 
significant inhibitory effect of an ETA receptor antagonist on the growth of CRC liver
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metastases. However, the present larger study does not do the same. There are 
important differences in the methodologies which will account for this.
A-127722 should be a more potent inhibitor than BQ-123 due to its greater 
specificity for ETA receptors. The concentrations used were both within the quoted 
ones in the original manufacturer’s data sheets. However, the mode of deliveries did 
differ. The pilot study used an intra-portal route for administration whereas the 
purpose of this study was to investigate the more amenable oral route and to this 
end the simplest way of designing this was to add the required dose to a fixed 
amount of water; the assumption is that rats have a predictable intake of water per 
day according to weight so that there was minimal variation in the concentrations of 
the agent between the rats. The direct oro-gastric route of administration, by 
injecting the agent directly via an oro-gastric tube was considered but not used as 
the rats soon develop an adversity to this route and administration for 17 days would 
have been very difficult without anaesthesia. Furthermore, the technique was 
considered cruel.
It is however, impossible to say what the bio-availability of the oral A-127722 in rats 
is. Furthermore, some rats were more unwell than others after the inoculation of the 
MC28 cells under general anaesthesia and during this period the water consumption 
may have varied significantly for a long period of time. If the agent has an increased 
efficacy at an early stage of the disease, then that window of time would have been 
missed while the rat was recovering. There were other concerns with our model. The 
post operative mortality rate was high as was the incidence of mesenteric deposits in 
the absence of liver metastases. The mesenteric deposits suggest either inadequate 
intravascular inoculation or preferential anchoring of the MC28 cell lines used in the 
mesentery. The MC28 cells might have been cross contaminated; higher passage
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numbers were less reliable in their inherent production of endogenous ET-1. The 
medium used for diluting the A-127722 (dextrose / sodium hydroxide / propylene 
glycol and ethanol) added further uncertainty in that it’s effect on the portal 
circulation is unknown. Several general animal housing issues were also raised 
around the time of running of this study.
There are other models that have been used and sited. Gervaz (2000) worked on 
syngeneic BD IX rats and injected DHD K12 colon carcinoma cells into the spleen to 
produce diffuse liver metastases. Subsequently, TNP-470, a potent angiogenesis 
inhibitor, was subcutaneously transplanted after tumour implantation on alternate 
days for 4 weeks. The authors were able to show a significant reduction in the 
growth of liver metastases. Lauwers (1999), working on 120 WAG/RIJ rats, induced 
colonic anastomotic tumour and then tested the effect of suramin, an anti angiogenic 
agent, on intra peritoneal injection. Surprisingly, the tumours grew in size in 
response to this agent. ETA receptor intraperitoneal blockade (Atrasentan) in murine 
tumour human ovarian carcinoma xenografts grown subcutaneously produced a 
65% inhibition in tumour growth (Rosano et al, 2004). Moreover it potentiated the 
effect of the chemotherapeutic agent, cisplatinum, significantly.
Anti-angiogenic therapy potentiates radiotherapy in tumour- bearing animals partly 
because the former reduces hypoxia in the tumour. Furthermore, a combination of 
anti-angiogenic and cytotoxic therapy has potential for cure in animals with tumours. 
The effect of the individual agents appears to be merely inhibitory.
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Chapter V 
Summary and Conclusion of Thesis
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Summary of findings:
1. ET-1 stimulates the growth of colorectal cancer and rat sarcoma cells in vitro. 
The effect had an optimal dose dependent on the cell line investigated.
2. The stimulant effect of ET-1 is mediated via its ETa receptor. Specific blocking
of the ETa receptor, using A-127722, reversed the ET-1 effect. An ETB receptor 
antagonist did not show any effect.
3. ET-1 increase mitosis as measured by BrDU uptake in the cell lines. 
Apoptosis was not altered by ET-1.
4. The increase in mitosis is thought to be mediated by a G protein subunit Go 
or Gi and was blocked by pertussis toxin, a specific blocker.
5. The ratio of ETA:ETB receptors found in human colorectal liver metastases
tissue was increased compared to normal liver tissue taken from the same patients. 
This correlated positively with findings in colorectal cancer and normal colorectal 
tissue from previous studies.
6. The oral administration of the ETA receptor antagonist, A-127722, in an 
animal model of colorectal cancer liver metastases did not show any significant 
outcome change. However, the model may have been inadequate. We used the 
MC28 cell line which is a sarcoma cell line. The numbers of rats that developed the 
liver metastases were small and the mode of oral delivery of the drug was not 
reliable enough. A previous pilot study using the same ETA receptor antagonist
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administered through an intraportal parenteral route did show a reduction in tumour 
load. Other animal models have used, amongst many techniques, subcutaneous 
tumours, intra splenic tumour injections and intra peritoneal drug administration.
Primary colorectal cancer is surgically curable. However, once there is metastasis 
the 5-year survival becomes much poorer and the median survival is less than 12 
months (Bengtsson G et al, 1981; Lahr CJ et al, 1983). Even the selected patients 
who benefit from resection only achieve 25-25% 5-year survival (Cady B et al, 1991; 
Fong et al, 1999; Choti MA et al, 1999). There is potential for improving outcome by 
reducing the incidence of metastases from colorectal primary tumours. ET-1 is a 
peptide over-expressed by nearly 100% of colonic cancers. A course of an ETA 
antagonist would be combined with resection of the primary tumour. Investigation of 
the role of ETA receptor antagonists in vivo may lead to a reduction in or inhibition of 
cancer cell metastases.
ET-1 antagonism, as a novel form of solid cancer therapy, may compliment 
conventional therapy. It has several potential advantages over conventional 
palliative therapy. In general anti-angiogenic therapy targets a small focus of 
endothelial cells in capillaries at sites of angiogenesis, bone marrow suppression, 
gastrointestinal symptoms or hair loss are unlikely side effects (Folkman J, 1995). 
Several issues need addressing in order to take this work forward:
1. The nature of the intracellular signalling following the activation of the G 
protein.
2. Does ET-1 expression by colorectal cancer and liver metastases correlate 
with survival?
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3. A better model for testing the efficacy of ETA receptor antagonists in animals.
4. What would be the ideal route of administration of the ETA receptor 
antagonist?
The four points outlined above should form the basis of further research into the 
viability of using ET receptor antagonism as adjuvant treatment for colorectal cancer 
and liver metastases.
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